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1 Introduction 
1.1 Obesity and Type 2 Diabetes Mellitus 
As the obesity epidemic shows no signs of abating, concern about this development 
has heightened during the last years. Obesity has been linked to numerous chronic conditions, 
including type 2 diabetes mellitus, hypertension, heart disease, stroke, and some forms of 
cancer. Therefore, increases in the prevalence of obesity carries potentially serious 
implications for the future health of populations and health care expenditures of countries (1, 
2). Although initially most abundant in developed countries, principally in the United States, 
obesity and overweight are now dramatically on the rise in low- and middle-income countries. 
Latest projections from the World Health Organization (WHO) indicated that in 2005 
approximately 1.6 billion adults were overweight and at least 400 million adults were obese 
(3). Furthermore, the WHO estimates that by 2015, approximately 2.3 billion adults will be 
overweight and more than 700 million will be obese. Moreover, childhood obesity is 
dramatically on the rise, as in 2005 at least 20 million children under the age of 5 years were 
considered overweight (3). 
The Body Mass Index (BMI), a simple index of weight-for-height, is one of the most 
commonly recommended and widely used methods for classifying overweight and obesity in 
adults. It is defined as the weight in kilograms divided by the square of the height in meters 
(kg/m2) (4). The WHO defines overweight as a BMI ≥ 25, and obesity as a BMI ≥ 30. 
However, while BMI classification provides a useful method for measurement of total 
adiposity, it needs adjustment for additional factors such as age, gender, and ethnicity. It is 
estimated that there are more than 300,000 obesity-attributable annual deaths and 80% of 
these occur among individuals with a BMI of more than 30 kg/m2 (5). Compared to 
individuals with a normal BMI, there is substantial risk of developing type 2 diabetes mellitus 
in individuals with a BMI > 35 (6, 7). 
A substantial portion of the health complications and costs attributed to obesity is 
related to type 2 diabetes mellitus; a progressive disease that is primarily defined by the level 
of hyperglycemia with concomitant hyperinsulinemia and leads to deterioration in multiple 
organs and systems. In particular, it increases the risk of microvascular damage (i.e. 
retinopathy, nephropathy and neuropathy) (8). Furthermore, it is associated with significant 
morbidity due to microvascular complications, increased risk of macrovascular complications 
(i.e. ischaemic heart disease, stroke and peripheral vascular disease), diminished quality of 
life and ultimately reduced life expectancy (1, 8). Estimations indicate that worldwide there 
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were 171 million people with type 2 diabetes mellitus in the year 2000 and this is estimated to 
increase to 366 million people by 2030 (9). Resistance to the biological effects of the peptide 
hormone insulin represents one of the hallmarks during the development of type 2 diabetes 
mellitus (10, 11) and obesity has been strongly associated with insulin resistance in 
normoglycemic persons and in individuals with type 2 diabetes mellitus (12, 13). 
Many studies have indicated that genetic factors account for a substantial portion of 
variation in human adiposity. A genome-wide search for type 2 diabetes mellitus-
susceptibility genes identified a common variant in the FTO (fat mass and obesity associated) 
gene that predisposes to type 2 diabetes mellitus through an effect on BMI (14). In addition, 
the importance of leptin, the leptin receptor and the melanocortin system in the control of 
human body weight has been demonstrated by identification of obese patients with mutations 
in leptin, the leptin receptor, proopiomelanocortin (POMC) or the melanocortin receptor 4 
(15, 16). However, although rare obesity syndromes caused by mutations in single genes have 
been described, by far the greatest proportion of obesity in humans is not due to mutations in 
single genes. Thus, the most common forms of human obesity, that account for the obesity 
epidemic worldwide, are more likely to arise from the interactions of multiple genes, 
environmental factors and behavior (15, 16). 
 
1.2 Energy Homeostasis 
Body mass and composition are ultimately influenced by the long-term balance 
between energy intake and energy expenditure. With positive energy balance, body mass 
increases in order to restore energy balance. On the other hand, a state of negative energy 
balance leads to a decrease in body mass. Thus, understanding the regulation of energy 
balance is crucial in the development of therapeutical strategies in the treatment of obesity 
(for review see (17-20)). 
Research over the last years suggested a key role for the central nervous system (CNS) 
in the control of energy homeostasis. Neuronal systems involved in regulation of energy 
intake, energy expenditure, and endogenous glucose production sense and integrate input 
from peripheral hormones and nutrient-related signals that convey information about body 
energy stores and energy availability (for review see (21)). In response, the brain activates 
anabolic pathways (inhibition of energy intake and endogenous glucose production) to restore 
energy balance. Conversely, a decreased neuronal input from these afferent signals activates 
catabolic responses that promote positive energy balance (increased energy intake and 
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endogenous glucose production). Afferent signals that convey information about body energy 
stores and energy availability include the pancreatic hormone insulin as well as the adipocyte-
derived hormone leptin. 
 
1.3 Insulin 
1.3.1 History, Structure and Biosynthesis 
In 1889, the physicians Oscar Minkowski and Joseph von Mering first noted that 
surgical removal of the pancreas led to the development of diabetes mellitus in dogs ((22), for 
review see (23)). Despite considerable effort, no significant progress was made in the 
isolation or characterization of the “antidiabetic factor” until 1921, when F. Banting, C. Best, 
J.J.R. Macleod and J. Collip finally identified a substance in extracts of the pancreas that had 
the remarkable ability to reduce blood glucose levels in diabetic animals; and by 1923 these 
pancreas extracts were being used to successfully treat diabetic patients (for review see (24, 
25)). In 1923, Banting and Macleod were awarded the Nobel Prize in Medicine for their 
discovery of insulin. 
Insulin, a 51 amino acid anabolic peptide hormone, is synthesized in the β-cells of the 
pancreatic islets of Langerhans, which are endocrine cells within the primarily exocrine 
pancreatic tissue. In the β-cells, insulin is cleaved from the inactive precursor proinsulin, 
which consists of two peptide chains linked by an intervening region called the C-peptide 
(26). Proinsulin is synthesized in the endoplasmatic reticulum, and then transported to the 
Golgi apparatus where it is packed into secretory granules and converted to native insulin and 
the C-peptide by the action of two endopeptidases and one carboxypeptidase (27, 28). 
Removal of the C-peptide results in a conformational change of the protein, which enables the 
interaction with its receptor, the insulin receptor (29). After binding to and activating its 
receptor, insulin is either released back into the circulation or degraded by the cell via 
endocytosis of the insulin receptor complex followed by the action of the insulin degrading 
enzyme (for review see (30)). 
 
1.3.2 Metabolic Effects 
Insulin release from the pancreatic β-cells is rapidly triggered in response to increased 
blood glucose levels, although insulin release is also stimulated by amino acids from ingested 
proteins, acetylcholine, cholecystokinin, glucose-dependent insulinotropic peptide (GIP) and 
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glucagon-like peptide (GLP)-1 (31-35). Moreover, plasma insulin levels are also directly 
correlated with the degree of body adiposity (36-38). Upon release, binding of insulin to its 
receptor induces a cascade of intracellular signaling events that regulate key cellular 
functions, including glucose transport and oxidation, synthesis of glycogen, triglycerides and 
proteins, and regulation of gene expression. Insulin acts on peripheral tissues, particularly on 
muscle cells and adipocytes, via translocation of the glucose transporter GLUT-4 into the cell 
membrane, thereby increasing glucose uptake in these tissues (39-41). Moreover, insulin 
promotes anabolic processes such as stimulation of amino acid uptake and protein synthesis in 
muscle, glycogen synthesis in liver and muscle as well as lipogenesis in adipose tissue. 
Catabolic processes, on the other hand, such as glycogenolysis, lipolysis and proteolysis are 
inhibited by insulin (for review see (31)).  
In addition, insulin controls hepatic glucose production through regulation of both 
glycogen metabolism and gluconeogenesis (for review see (42)). Prager et al. expanded the 
model of insulin’s direct hepatic effects by demonstrating that suppression of hepatic glucose 
production in obese, nondiabetic humans could also occur after peripheral insulin infusion, 
even when portal vein insulin concentrations remained unchanged, suggesting that insulin is 
also able to suppress hepatic glucose production through indirect hepatic actions (43). 
Subsequent work in dogs confirmed this notion (44-46), and, in 2002, Obici et al. defined the 
mediobasal hypothalamus, a region known to be involved in regulation of energy balance, as 
one important extrahepatic site of insulin action to regulate hepatic glucose production (47). 
They demonstrated that hypothalamic insulin signaling is required for insulin’s ability to 
suppress hepatic glucose production in euglycemic-hyperinsulinemic clamps of rats, a finding 
that was subsequently also described in mice (47, 48). Further recent work has indicated that 
hypothalamic insulin signaling is required for blood glucose lowering during insulin treatment 
of diabetes mellitus in rats (49). 
The finding that insulin, when infused into the brain, decreases food intake and body 
weight led to the proposal by Woods and Porte that insulin serves as an adiposity signal in the 
brain, where it provides a signal related to the amount of body fat and causes a long-term, net 
catabolic response, decreasing food intake and increasing energy expenditure (50-53). 
Peripheral circulating insulin has access to the brain via a saturable transporter across the 
blood-brain barrier and insulin receptors are widely expressed in the brain, with the highest 
concentrations in the olfactory bulb, hypothalamus, cerebral cortex, cerebellum and the 
hippocampus (54-57). Importantly, mice with a neuron-specific insulin receptor deficiency 
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are obese and display impaired fertility, further supporting a role for insulin receptor signaling 
in the regulation of fuel metabolism and reproduction (58).  
 
1.4 The Insulin Receptor 
The insulin receptor is present in virtually all vertebrate tissues, including classic 
insulin responsive tissues such as skeletal muscle, liver and adipose tissue, as well as tissues 
previously thought to be unresponsive to insulin like the CNS, the pancreas, lymphatic cells, 
endothelial cells or gonadal cells (59-62). The receptor gene is located on the short arm of 
human chromosome 19, is more than 150 kb in length and contains 22 exons, which encode a 
4.2 kb cDNA (63). The receptor, a typical ligand-activated receptor tyrosine kinase of which 
two different isoforms due to alternative splicing of exon 11 exist, is composed of two α-
subunits that are each linked to a β-subunit and to each other by disulfide bonds (64, 65). Both 
insulin receptor isoforms (IR-A and IR-B) display differences in ligand binding affinity, 
kinase activity, receptor internalization, recycling as well as intracellular signaling capacity 
and tissue distribution (66-71). From the two isoforms, IR-B is predominantly expressed in 
insulin target tissues (64, 66) that are responsible for glucose homeostasis such as liver, 
skeletal muscle and adipose tissue (72). 
Both subunits of the insulin receptor are products of a single gene and are derived 
from a polypeptide precursor by proteolytic processing (73). The α-subunits are located 
entirely outside of the cell and contain the insulin binding site(s), whereas the intracellular 
portion of the β-subunit contains the insulin-regulated tyrosine protein kinase (74). The family 
of ligand-activated receptor tyrosine kinases contains two other structurally related molecules, 
the insulin-like growth factor (IGF)-1 receptor and the insulin receptor-related receptor, an 
orphan receptor for which no ligand has been identified yet (75-77). 
The complete amino acid sequences, structural details and framework for the 
functional domains were determined by the cloning of the human insulin receptor precursor 
cDNA (73, 78). Subsequent cloning of the mouse and rat insulin receptor revealed a highly 
conserved sequence to the human insulin receptor gene (79). 
 
1.4.1 Molecular Mechanisms of Insulin Receptor Signaling 
Insulin exerts its pleiotropic functions by binding to and activating its membrane-
bound tyrosine kinase receptor. Binding of insulin to the α-subunit induces a conformational 
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change of the receptor, thereby activating the intrinsic tyrosine kinase activity of the β-
subunits leading to autophosphorylation of multiple tyrosine residues (Figure 1) (80). 
Phosphorylation of these residues creates a binding site for intracellular signaling proteins that 
are recruited to the receptor via their phosphotyrosine-binding (PTB) domain and 
subsequently become tyrosine phosphorylated (81-83). In addition, intracellular substrates 
contain a N-terminal Pleckstrin homology (PH) domain which, through interaction with 
inositol phosphates in the cell membrane, allows for the localization of the substrate to the 
membrane (84-86). Intracellular signaling molecules of the insulin receptor are the four 
closely related insulin receptor substrate (IRS 1 - 4) proteins and the growth factor receptor 
binding (Grb)2 protein-associated binder (Gab) proteins (87-93). These insulin receptor 
substrates serve, when tyrosine phosphorylated, as a docking platform for Rous sarcoma virus 
(Src)-homology 2 (SH2) domain containing signaling proteins, such as the regulatory subunit 
of the phosphatidylinositol (PI) 3 kinase, Grb2 and the SH2 domain containing phosphatase 
(Shp)-2, among which the most important and best studied is the PI3 kinase (94-98). Binding 
to the insulin receptor substrates is then followed by activation of the PI3 kinase and the 
Ras/Raf Mitogen-activated protein (MAP)-kinase pathway (Figure 1) (for review see (32)).  
The most common form of the widely expressed PI3 kinase consists of a 85 kDa 
regulatory subunit, p85, and a 110 kDa catalytic subunit, p110 (for review see (99)). 
Activation occurs when the SH2 domain of the regulatory subunit binds to the phosphorylated 
tyrosine residues of the activated IRS molecule. This relieves the inhibition of the catalytic 
subunit and serves to localize the catalytic subunit to the cell membrane, where the substrate 
of the PI3 kinase is located. PI3 kinase primarily catalyzes the phosphorylation of 
phosphatidylinositol (4,5) bisphophate (PIP2) to phosphatidylinositol (3,4,5) trisphosphate 
(PIP3) (Figure 1) (100, 101). PIP3, in turn, recruits and activates numerous other downstream 
molecules containing PIP3 binding domains (PH domains), including serine-threonine 
kinases, tyrosine kinases, and others. One of the key downstream targets is protein kinase B 
(PKB, also known as Akt), which upon binding to PIP3 via its PH domain translocates to the 
cell membrane and co-localizes with phosphoinositide-dependent protein kinase 1 (PDK1) 
(for review see (102)). The subsequent conformational change enables PDK1 to 
phosphorylate Akt, and thereby activating the enzyme. Activation of the IRS-PI3 kinase 
cascade is crucial for most of insulin’s well-known effects, including glucose transporter 
translocation, glycogen synthesis, protein synthesis and the regulation of gene transcription 
(Figure 1) (for review see (103)).  
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Figure 1: Insulin receptor signal transduction. 
Binding of insulin to the insulin receptor results in activation of the membrane-bound insulin receptor tyrosine 
kinase, which consists of two α-subunits and two β-subunits forming a α2β2 heterotetramer. Upon insulin 
binding to the extracellular α-subunits, the receptor undergoes a conformational change, activating the tyrosine 
kinase activity of the β-subunits, resulting in receptor autophosphorylation and subsequently in the 
phosphorylation of intracellular insulin receptor substrate (IRS) 1 proteins on tyrosine residues. These 
phosphorylation sites are located in domains that characterize them as binding sites for src-homology 2 (SH2) 
domain-containing proteins such as the p85-regulatory subunit of phosphatidylinositol 3 kinase (PI3 kinase) and 
the growth factor receptor binding protein (Grb) 2. Binding of these proteins to tyrosine-phosphorylated IRS 1 
proteins results in their activation, initiating downstream signals such as the activation of the Ras-Raf-MAPK 
cascade or activation of serine/threonine kinases downstream of PIP3. These signals finally result in the diverse 
biological effects of insulin signaling. Abbreviations: Akt, protein kinase B; MAPK, mitogen-activated protein 
kinase; mSOS, son of sevenless; PDK1, protein-dependent kinase 1; p110, catalytic subunit of PI3 kinase; PIP2, 
phosphatidylinositol (4,5) bisphosphate; PIP3, phosphatidylinositol (3,4,5) trisphosphate; PTEN, phosphatase 
and tensin homolog; Raf, proto-oncogene serine/threonine protein kinase; Ras, Ras small GTPase. 
 
1.5 Leptin 
In 1994, another prototypic adiposity signal was discovered as the ob (obese) gene 
product, which encodes the leptin protein (104). Mice carrying a mutation in the ob gene 
exhibit dramatic weight gain (ob/ob) (104), and a naturally occurring loss-of-function 
mutation of the leptin receptor in both CNS and periphery underlies the phenotype of obese 
and diabetic mice (db/db) (105). Leptin (leptos (Greek): thin) is primarily expressed in the 
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adipose tissue and, at lower levels, in gastric epithelium, placenta and testis (104, 106-108). 
The 16 kDa protein circulates in rodent and human plasma (109), and plasma leptin levels are 
highly correlated with adipose tissue mass and decrease in mice and humans after weight loss 
(110). In particular, the amount of ob gene expression per cell directly correlates with the 
lipid content and the size of individual adipocytes (111). Thus, plasma leptin levels have been 
found to be increased in obese humans as well as in multiple genetically induced forms of 
rodent obesity (110). Peripheral administration of leptin results in a dose-dependent decrease 
in body weight by reducing food intake and increasing energy expenditure in ob/ob and wild 
type mice, with weight loss restricted to adipose tissue but not lean mass (109, 112, 113). 
As shown by Cohen et al., the neuron-specific deletion of the leptin receptor 
resembles the phenotype of the db/db mouse (114), indicating that the major role of leptin 
action to control energy homeostasis is accounted for by its signaling in the CNS. Along this 
line, administration of leptin in the CNS decreases food intake and body weight in various 
species, underlining the pivotal role of leptin in the regulation of energy homeostasis in the 
CNS (for review see (21, 115, 116)). Circulating leptin is transported to the brain across the 
blood-brain barrier via a saturable process (117).  
In humans, rarely occurring loss-of-function mutations of the leptin gene result in 
morbid obesity, that can be rescued by leptin treatment (118, 119). However, the majority of 
obese patients develop overweight in the presence of elevated plasma leptin concentrations, 
indicative of leptin resistance (110, 118). Consistent with this, rats fed a high fat diet as a 
model of diet-induced obesity developed resistance to leptin’s anorectic effect in the presence 
of hyperleptinemia (120). However, studies indicate that leptin responsiveness may be 
restored if applied in combination with other drugs (121). 
 
1.5.1 Mechanisms of Leptin Receptor Signaling 
The leptin receptor is a cytokine receptor of which different isoforms exist, all arising 
from alternative mRNA splicing and/or proteolytic processing of the single lepr gene (122-
124). Among the different isoforms only the Lepr-B (ObRb) has been shown to activate 
intracellular signaling (123). ObRb is highly conserved among species and is critical for leptin 
action as observed in db/db mice, which indeed lack only the ObRb (122, 123, 125). Many 
effects of leptin on energy homeostasis are attributable to its action in the CNS, especially in 
the mediobasal hypothalamus, where ObRb is highest expressed (126). 
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Figure 2: Leptin receptor signal transduction. 
Binding of leptin to the long form of the leptin receptor (ObRb) leads to activation of janus kinase (JAK) 2 and 
subsequently to JAK2-mediated phosphorylation of three different intracellular tyrosine residues of the receptor. 
This results in the phosphorylation and activation of signal transducer and activator of transcription (STAT)3 
molecules. Activated STAT3 molecules form dimers, which translocate to the nucleus and activate target genes 
including suppressor of cytokine signaling (SOCS)3, resulting in inhibition of leptin signaling via a negative 
feedback loop. Additionally, phosphorylated JAK2 directly activates the IRS 1/PI3K signaling pathway, 
initiating downstream signals such as activation of serine/threonine kinases downstream of PIP3. Abbreviations: 
Akt, protein kinase B; IRS 1, insulin receptor substrate 1; PDK 1, protein-dependent kinase 1, PI3K, 
phosphatidyl inositol 3 kinase, PIP2, phosphatidylinositol (4,5) bisphosphate; PIP3, phosphatidylinositol (3,4,5) 
trisphosphate. 
 
ObRb consists of a single membrane-spanning domain and hormone binding to the 
receptor triggers the activation of a member of the janus kinase (JAK) family, JAK2 (127). 
Activation of the JAK2 associated tyrosine kinases leads to autophosphorylation of JAK2 on 
multiple tyrosine residues and phosphorylation of three tyrosine residues on the intracellular 
domain of ObRb to create a binding site for signal transducers and activators of transcription 
(STAT) molecules (Figure 2) (123, 127, 128). Activated phosphorylated STAT molecules 
dimerize and translocate to the nucleus where they act as a transcription factor to regulate 
gene expression via STAT-responsive elements (Figure 1) (127, 129, 130). Here, STAT3 
activates expression of the suppressor of cytokine signaling (SOCS)3 (131), thereby providing 
an intracellular negative feedback loop to leptin signaling. SOCS3 directly binds to JAK2, 
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thereby reducing phosphorylation of downstream molecules by JAK2 and attenuating leptin-
induced tyrosine phosphorylation of JAK2 (Figure 2) (132-135).  
Binding of leptin to the leptin receptor not only activates the JAK/STAT-pathway, but 
also PI3 kinase signaling via tyrosine-phosphorylation of IRS proteins and direct activation of 
the PI3 kinase by JAK2 (127, 136), thus providing a potential point of convergence and 
synergism with insulin-stimulated signals (Figure 2) (137). The importance of leptin-mediated 
activation of the PI3 kinase signaling pathway has been demontrated in IRS 2 deficient mice 
which develop hyperphagia and decreased energy expenditure in the presence of increased 
adiposity and circulating leptin concentrations, indicating leptin resistance (138). 
 
1.6 Central Regulation of Energy Homeostasis 
Already in the 1940s and 1950s, classic lesion experiments in the rodent hypothalamus 
could identify the brain as a critical organ in the regulation of body weight and energy 
homeostasis. In 1940, Hetherington demonstrated that destruction of the ventromedial 
hypothalamus (VMH) caused hyperphagia, obesity, and diabetes mellitus in rats (139), while 
lesions of the lateral hypothalamus (LH) carried out by Anand et al. resulted in a failure to eat 
and drink (140). It was thus concluded that the “satiety center” was located in the VMH and 
the “feeding center” in the LH. In 1953, Kennedy first proposed that hormonal signals are 
released into the blood stream in proportion to the body’s energy stores and are able to 
regulate body weight by influencing energy intake and expenditure (141). Parabiosis studies, 
in which the circulation of animals was surgically joined, demonstrated that food intake and 
body weight were drastically decreased in normal rats joined to obese VMH-lesioned rats. In 
contrast, VMH-lesioned rats continued to overeat and gain weight when parabiosed with 
VMH-lesioned or non-lesioned rats. These experiments provided direct evidence that an intact 
hypothalamus is required for the regulating action of hormonal satiety signals produced in 
obesity and created the link between circulating satiety signals and their hypothalamic target 
regions (142). 
Besides the brain’s ability to integrate peripheral hormonal signals in order to regulate 
energy intake and energy expenditure, it has long been suggested that the CNS plays an 
essential role in the control of peripheral blood glucose levels. The French physiologist 
Claude Bernard demonstrated more than 150 years ago that pricking of the floor of the fourth 
ventricle of the brain in rabbits results in glucosuria, and concluded that the CNS plays an 
essential role in the control of peripheral blood glucose levels (143). 
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1.6.1 The Hypothalamus 
In vertebrates, the hypothalamus is a part of the diencephalon that lies below the 
thalamus, building up the floor of the third cerebral ventricle. The mammalian hypothalamus 
consists of more than 40 histologically distinct nuclei and areas, which often can be further 
divided into subnuclei (144). Lesion and electrical stimulation studies identified distinct 
hypothalamic nuclei in control of feeding and satiety. Here, the arcuate nucleus (ARC), the 
paraventricular nucleus (PVN), the VMH, the dorsomedial hypothalamic nucleus (DMH) and 
LH are the nuclei, which have been shown to be involved in regulation of feeding behavior 
(Figure 3). Importantly, the hypothalamus is involved in many other behaviors than food 
intake, such as regulation of drinking behavior, body temperature, stress response, 
reproduction and the autonomous nervous system (for review see (145)). 
The ARC is located in the mediobasal hypothalamus adjacent to the third cerebral 
ventricle and the median eminence. Of the circumventricular organs, i.e. areas that lack a 
blood-brain barrier, the median eminence and its close relationship with the hypothalamic 
ARC plays an important role in controlling the entry of peripheral substances to neurons of 
the mediobasal hypothalamus (Figure 3) (146, 147). The PVN is located at the dorsal end of 
the third ventricle and represents a point of convergence for neuronal pathways implied in the 
regulation of energy balance, including projections from the ARC (144). Lesions of the PVN 
as well as the VMH, which is located directly above the ARC, results in hyperphagia and 
weight gain (Figure 3). The DMH is located dorsal of the VMH and major projections to this 
nucleus are provided by most other hypothalamic nuclei, including the ARC, the VMH, the 
PVN and the LH, indicating an integrative role for the DMH (148). The LH, a very large and 
heterogenous area, is the most extensively interconnected area of the hypothalamus, thereby 
allowing it to modulate different functions, including cognitive and autonomic functions (for 
review see (145)).  
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Figure 3: Schematic anatomical structure of the hypothalamus. 
Diagram of the mediobasal hypothalamus, showing major hypothalamic regions implicated in regulation of food 
intake and energy expenditure. Abbreviations: 3V, third ventricle; ARC, arcuate nucleus, DMH, dorsomedial 
hypothalamic nucleus; LH, lateral hypothalamus; ME, median eminence; VMH, ventromedial nucleus of the 
hypothalamus; PVN, paraventricular nucleus.  
 
1.6.2 The Central Melanocortin System and Regulation by Peripheral Hormones 
The melanocortin system has been considered as the most promising model to explain 
neuronal control in regulation of long-term energy balance (Figure 4) (for review see (21, 
149)). The ARC of the mediobasal hypothalamus is critical in this model. Here, two 
functionally opposing neuronal populations have been studied in great detail: the anorexigenic 
proopiomelanocortin (POMC)-expressing and the orexigenic agouti related peptide / 
neuropeptide Y (AgRP/NPY)-expressing neurons (Figure 4). AgRP and NPY are anabolic 
neuropeptides that stimulate feeding and reduce energy expenditure, while the catabolic 
neuropeptide POMC suppresses feeding and increases energy expenditure (150-152). 
The anorectic POMC neurons express POMC as a precursor protein which, dependent 
on the cell type-specific expression pattern of prohormone convertases, is processed to 
different bioactive products, including melanocyte-stimulating hormones (α-, β-, and γ-
MSH), adrenocorticotrophin (ACTH) and β-endorphin (153). Besides from the ARC, POMC 
is expressed in the pituitary, the nucleus tractus solitarius and in several peripheral tissues 
(154-156). Upon fasting, POMC mRNA levels are significantly reduced in the ARC, and 
expression is restored with refeeding (157).  
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Among the melanocyte-stimulating hormones, α-MSH reduces food intake and 
increases energy expenditure both in animals and humans (158-160). α- and β-MSH act on 
melanocortin receptor (MCR) type 3 and 4, which are G-protein coupled receptors that 
activate the adenylate cyclase and are expressed in the ARC, PVN, LH, VMH, and DMH 
(161-163). Recent elegant cell type-specific reconstitution experiments of MC4R on a null 
background in mice have defined single-minded homolog (SIM)-1-positive PVN neurons as 
the critical mediators of α-MSH stimulated anorexia (164). However, since energy 
expenditure remained unaltered in PVN/SIM1-reconstituted MC4R null mice, the nature and 
location of the energy expenditure controlling α-MSH target neurons remains elusive (164). 
The second principal neuronal population in the ARC are the orexigenic AgRP/NPY 
neurons. The orexigenic neuropeptide NPY is one of the most abundant neurotransmitters that 
is widely expressed throughout the brain with highest concentration in the ARC (165-167). 
NPY is a potent stimulator of food intake, reduces energy expenditure (168, 169), and central 
NPY administration promotes a state of positive energy balance and increased fat storage 
(170).  
AgRP acts as an inverse agonist of the MC3/4R and prevents the anorectic effect of α-
MSH. Accordingly, overexpression of the Agouti protein, an AgRP-like peptide results in the 
obese, hyperphagic phenotype of the Agouti (Ay) mouse (171). The only peripheral tissue 
with detectable AgRP expression is the adrenal gland (171).  
AgRP mRNA levels in the ARC are increased upon fasting (157), and reduction of 
hypothalamic AgRP mRNA results in an increased metabolic rate and reduction of body 
weight without affecting food intake (172). The pivotal role of these cells in the acute 
regulation of feeding in adult mammals has been further substantiated by toxin-mediated 
AgRP neuron ablation: ablation of these neurons in adult mice led to a hypophagic phenotype 
(173, 174). However, this phenotype of AgRP neuron-ablated mice conflicts that of 
NPY/AgRP single or double knockout mice (175), indicating that either developmental 
compensation accounts for the lack of a phenotype in the latter mice, or alternative 
neuropeptides or –transmitters are released from these cells. Indeed, AgRP neurons are 
GABAergic and thereby account to a large extend for the GABAergic innervation on 
neighbouring POMC cells (Figure 4) (176). Strikingly, acute ablation of AgRP neurons in 
adult mice causes disinhibition of neurons, as assessed by cFos immunoreactivity, in 
numerous brain sites including the ARC, PVN, DMH, medial preoptic area, lateral septum, 
and nucleus of the solitary tract (177). Consistent with a role for GABA-signaling in AgRP 
neurons, AgRP cell-restricted inactivation of the vesicular GABA transporter results in 
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leanness (178). Very recent studies have demonstrated that GABAergic AgRP neuron 
projections into the parabrachial nucleus are critical for the maintenance of feeding (179). 
Both, POMC and AgRP/NPY neuronal populations express insulin and leptin 
receptors and are targeted by the respective hormones (57, 58, 115), and large body of 
evidence has revealed an important role for leptin-activated STAT3 signaling in the CNS and 
POMC/AgRP neurons specifically in control of energy homeostasis. Neuron-specific 
disruption of STAT3 results in hyperphagia, obesity, diabetes and infertility (180). Along this 
line, mice with disruption of STAT3 specifically in leptin receptor-expressing neurons 
develop profound obesity (181). Further substantiating a role for STAT3 signaling in 
POMC/AgRP neurons for maintaining normal energy homeostasis, lack of leptin receptor 
signaling or inactivation of STAT3 specifically in POMC neurons results in obesity and other 
elements of the metabolic syndrome in rodents (182, 183), and deletion of STAT3 in 
AgRP/NPY neurons results in modest weight gain accompanied by mild hyperphagia (184). 
Interestingly, mice with a constitutive activation of STAT3 signaling specifically in AgRP 
neurons are lean due to increased locomotor activity (185), assigning AgRP neurons and 
specifically STAT3 signaling a role in control of locomotor activity. Administration of leptin 
to the ARC stimulates expression of POMC (115, 186) and inhibits expression of AgRP and 
NPY (187, 188). Moreover, administration of a MC4R antagonist attenuates the anorexigenic 
response to leptin (189).  
Insulin fails to activate STAT3 signaling and thus alternative intracellular signaling 
pathways mediating insulin-evoked anorexia via control of the melanocortin system should 
exist. Since intracellular signaling pathways of both insulin and leptin converge at the level of 
the PI3 kinase (190), this pathway provided an excellent candidate for convergence of insulin 
and leptin action. Indeed, blockade of PI3 kinase activation inhibits both insulin’s and leptin’s 
acute anorexigenic effect in rats, indicating an important role for PI3 kinase activation in 
mediating the intracellular effects of both hormones (136, 191). Subsequently, it was 
demonstrated that insulin and leptin evoked PI3 kinase activation results in Akt-mediated 
phosphorylation of the transcription factor forkhead-O transcription factor (FOXO)1, thus 
leading to disinhibition of POMC transcription (186, 192). Central administration of insulin 
results in increased POMC and decreased NPY expression, without affecting AgRP 
expression (187, 193, 194). Besides regulating gene expression, PI3 kinase signaling and 
especially its product PIP3 has been shown to regulate cell excitability by binding to the 
regulatory subunit of ATP-dependent potassium channels (KATP channels) (195). 
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Figure 4: Central regulation of energy homeostasis. 
The arcuate nucleus (ARC) contains both NPY/AgRP and POMC neurons, which are located close to the blood-
brain barrier, where they have preferential access to peripheral humoral signals such as the pancreas-derived 
hormone insulin and the adipocyte-secreted hormone leptin as well as nutritional signals such as glucose and free 
fatty acids. Both neuronal populations exert potent effects on energy balance mediated by their characteristic 
neuropeptides, which allow modulation of second order neurons. POMC neurons project predominantly to 
second order neurons in the paraventricular nucleus (PVN) of the hypothalamus, where the POMC cleavage 
product α-MSH acts on melanocortin (MC) 4 receptors to suppress food intake. AgRP serves as an inverse 
agonist for the MC4 receptor, thus counteracting the function of α-MSH. In the ARC AgRP/NPY neurons 
provide inhibitory input onto POMC neurons via synaptic release of the transmitter GABA (γ-aminobutyric 
acid). AgRP/NPY and POMC neurons sense and integrate peripheral signals related to the amount of body fat 
such as insulin and leptin to cause a long-term, net catabolic response, decreasing food intake, increasing energy 
expenditure and regulating hepatic glucose production. Abbreviations: AgRP, agouti-related peptide; NPY, 
neuropeptide Y; POMC, proopiomelanocortin, α-MSH, α-melanocyte-stimulating hormone. [Adapted from 
Schwartz MW, Porte D; Diabetes, obesity, and the brain; 2005; (19)] 
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KATP channels were initially identified as metabolic sensors in the pancreas, where 
they sense elevated glucose levels through changes in ATP concentrations as a result of 
glucose metabolism in the cytoplasm. Elevated ATP concentrations lead to the closure of 
KATP channels, thereby opening voltage-dependent calcium channels, increasing intracellular 
calcium concentration, and thus triggering vesicle release (196). 
KATP channels are widely expressed in different cell types of the brain: glia cells and 
neurons of the hippocampus and the hypothalamus (197-199), including POMC- and 
AgRP/NPY-expressing neurons. PIP3 modulates KATP channel activity via three different 
proposed mechanisms: (a) PIP3 increases the probability that KATP channels are open, which 
indirectly lowers the ability of ATP to inhibit the channels; (b) PIP3 directly decreases ATP 
binding to the channel (195, 200, 201); and (c) PIP 3 modulates KATP channel activity by 
degradation of local actin filaments around KATP channels (137). 
Recent studies have addressed the role of PIP3 mediated KATP channel modulation in 
hypothalamic neurons with regard to energy and glucose metabolism. Constitutive activation 
of PIP3 formation in POMC cells by conditional ablation of the phospholipid phosphatase and 
tensin homolog (PTEN), a negative regulator of PI3 kinase signaling, results in hyperphagia, 
diet-sensitive obesity, and leptin resistance (202). Moreover, transgenic expression of a 
mutant subunit that prevents ATP-mediated closure of KATP channels resulted in impaired 
whole-body response to a systemic glucose load although with no obvious effect on body 
weight (203). 
However, insulin and leptin receptors are expressed not only in the ARC, but also in 
the VMH, the LH and other hypothalamic sites, as well as in neurons of the midbrain (ventral 
tegmental area and substantia nigra) (56, 126, 204). Here, expression of the insulin and the 
leptin receptor and their functional signaling in dopaminergic neurons of the ventral tegmental 
area provides an interesting link between the hormonal control of food intake and the reward 
system (205-208). 
 
1.7 The Dopaminergic System of the Brain 
Regarding the functional components and brain substrates of reward, Berridge et al. 
proposed a model where they distinct between the components ‘wanting’ (appetite/incentive 
behavior) and ‘liking’ (pleasure/palatability) of food (209). Mediation of ‘wanting’ in terms 
of food reward involves in part the mesolimbic dopamine system, the nucleus accumbens and 
the amygdala (209). 
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Dopamine is a highly conserved catecholaminergic neurotransmitter involved in 
movement, goal-directed behavior, cognition, attention, and reward (for review see (210, 
211)). It is utilized predominantly in the brain, where it controls the function of the basal 
nuclei and their associated projections. In the peripheral nervous system, it is used as a 
neurotransmitter in a few peripheral neuronal groups, but primarily serves as the substrate for 
the synthesis of norepinephrine and epinephrine in sympathetic neurons and the adrenal 
medulla (211, 212).  
Dopamine is synthesized by hydroxylation of the amino acid L-tyrosine to L-
dihydroxyphenylalanine (L-DOPA) via the enzyme tyrosine hydroxylase, the rate-limiting 
enzyme in catecholamine biosynthesis, and subsequent decarboxylation of L-DOPA by 
aromatic L-amino acid decarboxylase (dopa decarboxylase) (for review see (213)). In 
neurons, dopamine is stored in vesicles at the presynaptic nerve terminals, and is released into 
the synapse in response to a presynaptic action potential. Released dopamine activates its 
postsynaptic receptors, as well as presynaptic dopamine (D) 2 receptors to inhibit further 
release of the neurotransmitter. Extracellular dopamine is cleared from the synapses via the 
dopamine transporter (DAT) and inactivated by monoamine oxidase (MAO) and catechol-O-
methyl-transferase (COMT) (213, 214). 
The first dopamine receptors were identified by their ability to regulate cyclic 
adenosine monophosphate (cAMP) production and were shown to be the targets of 
neuroleptic agents (215). This defined two classes of dopamine receptors, D1 and D2, which 
respectively stimulate and inhibit cAMP production and can be differentiated 
pharmacologically, biologically, physiologically and by their anatomical distribution (for 
review see (216)). Subsequent cloning of these receptors demonstrated two D1-like receptors 
(D1 and D5) and three D2-like receptors (D2, D3, and D4). D1 and D2 are most abundant in 
the neostriatum, which comprises the caudate nucleus, putamen and nucleus accumbens. 
Here, they are enriched in distinct populations of striatal neurons, although there is a certain 
level of co-expression. All dopamine receptor subtypes are members of a large guanosine 
triphosphate-binding (G) protein-coupled receptor family, which is characterized by seven 
transmembrane hydrophobic domains, an extracellular N- and an intracellular C-terminus. 
Downstream effects are either inhibitory or stimulatory, depending on the types of G protein 
linked to the receptor – dopamine D1 and D5 receptors are linked to inhibitory G proteins, 
whereas dopamine receptor D2, D3 and D4 are linked to stimulatory G proteins (for review 
see (216)).  
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Dopamine neurons innervating the dorsal striatum (caudate nucleus and putamen 
(CPu)) are located in the substantia nigra (SN), while those innervating the ventral striatum 
(nucleus accumbens (NAc)) and the prefrontal cortex are located in the ventral tegmental area 
(VTA) (217). 
The dopamine reward system, especially the projections from the VTA to the NAc, are 
well known for its link to drug addiction, and the rewarding aspects of food and sex (218, 
219). In contrast, bradykinesia and impairment in movements, the characteristic symptoms of 
Parkinsons’s Disease, are caused by impaired dopamine signaling to the CPu, which is based 
on the degeneration of dopaminergic neurons in the SN (for review see (220)).  
Midbrain dopaminergic neurons fire in bursts – a repetitive occurrence of groups of 
action potentials with short interspike intervals –, which is associated with the presentation of 
rewarding stimuli (221-223). Such burst firing results in an efficient release of dopamine from 
the nerve terminals and soma / dendrites (224), which helps an animal to highlight important 
environmental signals while suppressing irrelevant ones. Importantly, mice with selective 
inactivation of the tyrosine hydroxylase gene, the rate-limiting enzyme in dopamine 
biosynthesis, become hypophagic, hypoactive and die of starvation by 3 to 4 weeks of age 
(225).  
 
1.7.1 Peripheral Hormonal Signals in Food Reward 
Neuronal mechanisms underlying food reward may be closely related or similar to 
mechanisms of drug reward. Food and water are naturally rewarding and motivating stimuli, 
which promote burst firing of dopamine neurons, thereby facilitating goal-directed behavior 
towards the acquisition of food or water (222, 223, 226, 227). The brain regions activated by a 
food reward stimulus (e.g. highly palatable food) are the same regions responsive to drugs of 
abuse and involved in the development of drug addiction (for review see (228, 229)). There is 
also evidence that dysregulation of those drug reward circuits is involved in the development 
of obesity. Imaging studies in humans demonstrated that D2 receptor availability is decreased 
in obese individuals in proportion to their BMI (230), and treatment of ob/ob mice with 
dopamine D1/D2 receptor agonists normalizes hyperphagia, body weight gain, 
hyperglycemia, and hyperlipidemia (231). Notably, chronic food restriction and maintenance 
of low body weight increase the self-administration and motor-activating effects of abused 
drugs (232-234). By using a lateral hypothalamic self-stimulation rate frequency method, Carr 
et al. could demonstrate that food restriction augments the rewarding effect of diverse drugs 
of abuse (235). Electrical self-stimulation of a subset of neurons in the LH results in an 
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induced food intake in rats and this effect is augmented with food restriction (236). 
Furthermore, self-administration of food, and the ability of food to condition an animal to a 
place preference are increased with food deprivation (237-240).  
Both insulin and leptin, when administered locally to the brain, are able to reverse the 
shifted threshold of LH self-stimulation after food restriction (241, 242). Moreover, 
intracerebroventricular (icv) administered leptin attenuates the acute food deprivation-induced 
relapse to heroin self-administration in rats (243). Furthermore, peripheral applied leptin 
reverses sucrose-conditioned place preference in food-restricted rats (244). Finally, studies 
have implicated the IRS 2-Akt signaling pathway as an important regulator of dopamine cell 
morphology and opiate reward (245). Taken together, insulin and leptin may play a role in 
modulating the reward system in the CNS. 
Activity of the dopaminergic midbrain system is known to be involved in motivational 
driven behaviors, and the aspect of reward or motivation can be tested in different behavioral 
paradigms. Figlewicz et al. analyzed the ability of icv-administered insulin and leptin at 
physiological doses, which do not cause a change in body weight or food intake, to modify 
performance of an animal in such food reward tasks in ad libitum fed rats. To evaluate 
whether insulin is able to alter performance of a sucrose lick task, which is known to be 
dependent on intact dopaminergic signaling, the authors tested the effect of icv insulin and the 
selective D2 receptor antagonist raclopride. Although ineffective on its own, icv insulin 
combined with raclopride significantly suppressed sucrose lick rate in a five-minute task 
(246), indicating that insulin indeed could decrease the reward value of a sucrose solution. 
The conditioned place preference (CPP) task, which also depends on intact dopaminergic 
signaling in the CNS (238, 244), evaluates the preferences for environmental stimuli that have 
been associated with a reward (food or drug). CPP to a high fat diet is blocked in ad libitum 
fed rats given icv insulin or leptin (247), again indicating that insulin and leptin can influence 
the reward value of food. Finally, in a sucrose self-administration task, in which the 
motivation to work for a sucrose reward is measured by pressing a lever, both insulin and 
leptin icv decreased the number of presses on the lever (248). These results indicate that both 
insulin and leptin are involved in multiple aspects of food reward: hedonics, place preference, 
and the motivation to work for a reward (for review see (249)). 
Consistent with a modulatory role of these hormones on the reward system, insulin 
and leptin receptors are co-expressed with tyrosine hydroxylase - a marker for dopamine 
neurons – in the VTA and SN (204). Furthermore, insulin or leptin administration into the 
VTA results in an increased formation of PIP3 as compared to control injections (249). Here, 
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PIP3, the product of the PI3 kinase, serves as an indicator for a functional signaling pathway. 
Furthermore, it has been shown that leptin receptor mRNA is expressed in the VTA and in 
response to peripheral, icv or direct VTA leptin injection the intracellular JAK-STAT 
pathway becomes activated (205, 242). This evidence suggests that the insulin and leptin 
receptors are functional, and that the respective signaling pathways are indeed activated in 
these dopaminergic cells. Moreover, activation of the JAK-STAT pathway has been shown to 
be critical for the effect of leptin in the VTA to decrease food intake (205). Finally, 
electrophysiology studies revealed that leptin significantly reduces the firing rate of 
dopaminergic neurons in the VTA (205).  
 
1.8 Objectives 
Obesity and type 2 diabetes mellitus are intimately connected diseases and their 
incidences are steadily increasing worldwide. Therefore, there is an urgent need for the 
development of therapeutical approaches to treat the obesity epidemic. The central nervous 
system serves as a central regulator of energy homeostasis by integrating hormonal signals 
from the periphery of the organism such as insulin and leptin to adapt food intake, energy 
expenditure and glucose metabolism to the degree of peripheral energy sources. Receptors for 
both insulin and leptin are expressed in various regions of the brain and extensive research 
over the last 30 years has identified the mediobasal hypothalamus, a region mainly involved 
in the regulation of energy homeostasis, as a major target for insulin and leptin. To precisely 
define the hypothalamic neuronal populations mediating insulin’s central effects on energy 
and glucose homeostasis in vivo, the insulin receptor was genetically deleted in POMC- and 
AgRP-expressing neurons of mice, and physiological parameters in terms of energy 
homeostasis and glucose metabolism were analyzed in these animals. Furthermore, food 
palatability and reward are thought to be major factors involved in the regulation of food 
intake and energy homeostasis, and insulin has been shown to modulate the reward system of 
the brain. To analyze the role of insulin signaling in the dopaminergic system of the brain in 
vivo, the insulin receptor was genetically ablated in dopaminergic cells, and mice were 
analyzed in terms of energy homeostasis. 
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2 Materials and Methods 
2.1 Chemicals and Biological Material 
Size markers for agarose gel electrophoresis (Gene Ruler™ DNA Ladder Mix) and for 
SDS-PAGE (Page Ruler™ Prestained Protein Ladder Mix) were obtained from MBI 
Fermentas, St. Leon-Rot, Germany. RedTaq® DNA Polymerase and 10x RedTaq® buffer were 
purchased from Sigma-Aldrich, Seelze, Germany. All chemicals used in this work are listed 
in table 1 and all enzymes used in this work are listed in table 2. Solutions were prepared with 
double distilled water.  
 
Table 1: Chemicals 
Chemical Supplier 
β-Mercaptoethanol (β-ME) AppliChem, Darmstadt, Germany 
ε-aminocaproic acid Sigma-Aldrich, Seelze, Germany 
0.9% saline (sterile) Delta Select, Pfullingen, Germany 
2,2,2-Tribromoethanol (Avertin®) Sigma-Aldrich, Seelze, Germany 
2-Deoxy-D-[1-14C]-Glucose Amersham, Freiburg, Germany 
2-Methyl-2-Butanol Sigma-Aldrich, Seelze, Germany 
Acetic acid Merck, Darmstadt, Germany 
Acetone KMF Laborchemie, Lohmar, Germany 
Acrylamide Roth, Karlsruhe, Germany 
Agarose Peqlab, Erlangen, Germany 
Agarose (Ultra Pure) Invitrogen, Karlsruhe, Germany 
Ammonium Acetate Merck, Darmstadt, Germany 
Ammoniumpersulfat (APS) Sigma-Aldrich, Seelze, Germany 
Aprotinin Sigma-Aldrich, Seelze, Germany 
Avidin Biotin Complex-Vectastain Elite  Vector, Burlingame, USA 
Bacillol® Bode Chemie, Hamburg, Germany 
Barium hydroxide Fluka, Sigma-Aldrich, Seelze, Germany 
Benzamidine Sigma-Aldrich, Seelze, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Seelze, Germany 
Bromphenol blue Merck, Darmstadt, Germany 
Calcium chloride Merck, Darmstadt, Germany 
Chloroform Merck, Darmstadt, Germany 
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Count offTM NEN® Research Products, Boston, USA 
D-[3-3H]-Glucose Amersham, Freiburg, Germany 
Desoxy-Ribonucleotid-Triphosphates (dNTPs) Amersham, Freiburg, Germany 
Diaminobenzidin (DAB) Dako, Denmark 
Dimethylsulfoxide (DMSO) Merck, Darmstadt, Germany 
di-Natriumhydrogenphosphat Merck, Darmstadt 
Enhanced chemiluminescence (ECL) Kit Perbio Science, Bonn, Germany 
Ethanol, absolute AppliChem, Darmstadt, Germany 
Ethidium bromide Sigma-Aldrich, Seelze, Germany 
Ethylendiamine tetraacetate (EDTA) AppliChem, Darmstadt, Germany 
Forene® (isoflurane) Abbot GmbH, Wiesbaden, Germany 
Glucose 20% DeltaSelect, Pfullingen, Germany 
Glycerol Serva, Heidelberg, Germany 
Glycine Applichem, Darmstadt, Germany 
HEPES Applichem, Darmstadt, Germany 
Hydrochloric acid (37 %) KMF Laborchemie, Lohmar, Germany 
Hydrogen peroxide Sigma-Aldrich, Seelze, Germany 
Insulin Novo Nordisk, Bagsværd, Denmark 
Isopropanol (2-propanol) Roth, Karlsruhe, Germany 
Kaisers Glycerin Gelatine Merck, Darmstadt, Germany 
Magnesium chloride Merck, Darmstadt, Germany 
Methanol Roth, Karlsruhe, Germany 
Nitrogen (liquid) Linde, Pullach, Germany 
Octenisept® Schülke & Mayr, Norderstedt, Germany 
Paraformaldehyde (PFA) Fluka, Sigma-Aldrich, Seelze, Germany 
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich, Seelze, Germany 
Phosphate buffered saline (PBS) Gibco BRL, Eggenstein, Germany 
Potassium chloride Merck, Darmstadt, Germany 
Potassium hydroxide Merck, Darmstadt, Germany 
Ready Safe™, Liquid Scintillation Cocktail Beckman Coulter, Fullerton, USA 
Sodium acetate AppliChem, Darmstadt, Germany 
Sodium chloride AppliChem, Darmstadt, Germany 
Sodium citrate Merck, Darmstadt, Germany 
Sodium dodecyl sulfate AppliChem, Darmstadt, Germany 
Sodium fluoride Merck, Darmstadt, Germany 
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Sodium heparin (Liquemin®) Roche, Grenzach-Wyhlen, Switzerland 
Sodium hydroxide AppliChem, Darmstadt, Germany 
Sodium orthovanadate Sigma-Aldrich, Seelze, Germany 
Somatostatin Sigma-Aldrich, Seelze, Germany 
Sucrose AppliChem, Darmstadt, Germany 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich, Seelze, Germany 
Tissue Freezing Medium  Jung, Heidelberg, Germany 
Tramadolhydrochlorid (Tramal®) Grünenthal, Aachen, Germany 
Trishydroxymethylaminomethane (Tris) AppliChem, Darmstadt, Germany 
Triton X-100 Applichem, Darmstadt, Germany 
Tween 20 Applichem, Darmstadt, Germany 
Vectashield® Mountin Medium with DAPI Vector, Burlingame, USA 
Western Blocking Reagent Roche, Mannheim, Germany 
Zinc sulfate Fluka, Sigma-Aldrich, Seelze, Germany 
 
Table 2: Enzymes 
Enzymes Supplier 
DNase, RNase-free Promega, Madison, WI, USA 
EuroScript Reverse Transcriptase Eurogentec, Seraing, Belgium 
Proteinase K Roche, Basel, Switzerland 
Red Taq DNA Polymerase Sigma-Aldrich, Seelze, Germany 
RNase Inhibitor Eurogentec, Seraing, Belgium 
 
2.2 Molecular Biology 
Standard methods of molecular biology were performed according to protocols 
described by J. Sambrook (250), unless stated otherwise. 
 
2.2.1 Isolation of Genomic DNA 
Mouse tail biopsies were incubated 1 h in lysis buffer (100 mM Tris-HCl [pH 8.5], 5 
mM EDTA, 0.2% (w/v) SDS, 0.2 M NaCl, 500 mg/ml proteinase K) in a thermomixer 
(Eppendorf, Hamburg, Germany) at 56°C. DNA was then precipitated from the solution by 
adding an equivalent of isopropanol. After washing with 70 % (v/v) EtOH and centrifugation, 
the DNA pellet was dried at 60°C for 10 min and resuspended in double distilled water 
(ddH2O). 
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2.2.2 Quantification of Nucleic Acids 
DNA and RNA concentrations were assessed by measuring the sample absorption at 
260 nm with a NanoDrop ND-1000 UV-Vis Spectrophotometer (Peqlab, Erlangen, 
Germany). An optical density of 1 corresponds to approximately 50 µg/ml of double stranded 
DNA and to 38 µg/ml of RNA. To assess purity of nucleic acids, the ratio of absorptions at 
260 nm versus 280 nm was calculated, as proteins absorb maximum at 280 nm. An 
OD260/OD280 ratio of 2 refers to pure nucleic acids, lower values display protein 
contaminations. 
 
2.2.3 Polymerase Chain Reaction (PCR) 
The PCR method (251, 252) was used to genotype mice for the presence of floxed 
alleles or transgenes with customized primers listed in Table 3. Reactions were performed in a 
Thermocycler iCycler PCR machine (Bio-Rad, München, Germany) or in a Peltier Thermal 
Cycler PTC-200 (MJ Research, Waltham, USA). All amplifications were performed in a total 
reaction volume of 25 µl, containing a minimum of 50 ng template DNA, 25 pmol of each 
primer (listed in table 3), 25 µM dNTP Mix, 10 x RedTaq® reaction buffer and 1 unit of 
RedTaq® DNA Polymerase. Standard PCR programs started with 4 min of denaturation at 
95°C, followed by 30 cycles consisting of denaturation at 95°C for 45 seconds (sec), 
annealing at oligonucleotide-specific temperatures for 30 sec and elongation at 72°C for 30 
sec, and a final elongation step at 72°C for 7 min. 
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Table 3: Oligonucleotides used for genotyping. 
All primer sequences are displayed in 5’-3’ order. Primer orientation is designated “sense” when coinciding with 
transcriptional direction. All primers were purchased from Eurogentec, Cologne, Germany. 
 
Primer Sequence (5’-3’) TAnnealing [°C] Orientation 
AgRPCre5’ CCCTAAGGATGAGGAGAGAC 54 sense 
Cre-intern-rev-3 ATGTTTAGCTGGCCCAAATGT 50 antisense 
AgRP-3 CCAACCTGACCATACTCACC 54 antisense 
PomcCre N16R TGGCTCAATGTCCTTCCTGG 54 sense 
PomcCre N57R CACATAAGCTGCATCGTTAAG 50 antisense 
PomcCre AA03 GAGATATCTTTAACCCTGATC 49 antisense 
IR-5 GATGTGCACCCCATGTCTG 53 sense 
IR-3 CTGAATAGCTGAGACCACAG 52 antisense 
IR-delta-5 GGGTAGGAAACAGGATGG 50 sense 
Th-5 CACCCTGACCCAAGCACT 53 sense 
Th-3 CTTTCCTTCCTTTATTGAGAT 47 antisense 
CreUD GATACCTGGCCTGGTCTG 53 antisense 
GFP-5 CTGGTCGAGCTGGACGGCGACG 64 sense 
GFP-3 CAGGAACTCCAGCAGGACCATG 59 antisense 
LacZ-5 ATGGATGAGCAGACGATGGT 52 sense 
LacZ-3 TTTGATCCAGCGATACAGCG 52 antisense 
 
PCR-amplified DNA fragments were applied to 1% - 2% (w/v) agarose gels (1 x TAE, 
0.5 mg/ml ethidium bromide) and electrophoresed at 100 V. 
 
2.2.4 RNA Extraction, RT PCR and Quantitative Realtime PCR 
Mouse tissues were dissected and homogenized using an Ultra Turrax homogenizer 
(IKA, Staufen, Germany). Total RNA was extracted using the Qiagen RNeasy Kit (Qiagen, 
Hilden, Germany). After treatment with RNase-free DNase, 200 ng of each RNA sample were 
reversely transcribed using the Eurogentec RT Kit (Eurogentec, Cologne, Germany) 
according to manufacturer’s protocols. The cDNA was subsequently amplified using 
TaqMan Universal PCR-Master Mix, NO AmpErase UNG with TaqMan Assay on 
demand kits (Applied Biosystems, Foster City, USA) with the exception of the detection of 
POMC mRNA (see Table 4). Customized primers were used for the detection of POMC 
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mRNA: POMC sense 5’-GACACGTGGAAGATGCCGAG-3’; anti-sense, 5’-
CAGCGAGAGGTCGAGTTTGC-3’; probe sequence, 5’-FAM-
CAACCTGCTGGCTTGCATCCGG-TAMRA-3’. Relative expression of samples was 
adjusted for total RNA content by glucuronidase beta (Gusb) and hypoxanthine guanine 
phosphoribosyl transferase (Hprt)-1 RNA quantitative Realtime PCR. Calculations were 
performed by a comparative method (2-ddCT). Quantitative PCR was performed on an ABI-
PRISM 7700 Sequence Detector (Applied Biosystems, Foster City, CA, USA). Assays were 
linear over 4 orders of magnitude. 
 
Table 4: Probes used for Realtime PCR. 
All probes were purchased from Applied Biosystems, Foster City, USA. 
Probe Catalogue N° Probe Catalogue N° 
AgRP Mm00475829_g1 DAT Mm00438388_m1 
Ccl2 Mm00441242_m1 Ddc Mm00516688_m1 
Ccl3 Mm00441258_m1 Gusb Mm00446953_m1 
Ccl5 Mm01302428_m1 Hprt-1 Mm00446968_m1 
COMT Mm00514377_m1 IL-6 Mm00446190_m1 
Cxcl2 Mm00436450_m1 MAOB Mm00558004_m1 
D1R Mm01353211_m1 NPY Mm00445771_m1 
D2R Mm00438541_m1 TH Mm00447557_m1 
D3R Mm00432887_m1 TNF-α Mm00443258_m1 
 
2.3 Cell Biology 
2.3.1 Histological Analysis and Immunohistochemistry 
2.3.1.1 Immunohistochemistry 
IR∆POMC and IR∆AgRP mice were mated with LacZ reporter mice (253). IR∆POMC/LacZ, 
IR∆AgRP/LacZ and wildtype reporter (PomcCre-, AgRPCre-LacZ) mice were anesthetized and 
transcardially perfused with physiologic saline solution followed by 4% paraformaldehyde 
(PFA) in 0.1 M phosphate buffered saline (PBS; pH 7.4). The brains were dissected, post-
fixed in 4% PFA at 4°C, transferred to 20% sucrose for 6 h and frozen in tissue freezing 
medium. Then, 25 µm thick free-floating coronal sections were cut through the ARC using a 
freezing microtome (Leica). The sections were collected in PBS/azide (pH 7.4) and washed 
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extensively to remove cryoprotectant. Subsequently, the sections were treated with 0.3% 
H2O2 in PBS for 20 min to quench endogenous peroxidase activity. Following pretreatments, 
the sections were processed using the Renaissance® TSA™ Fluorescence Systems Tyramide 
Signal Amplification Kit (PerkinElmer™) according to manufacturer’s guidelines (primary 
antibody: rabbit anti-lacZ, # 55976; Cappel; secondary antibody: goat anti-rabbit peroxidase 
labeled, Vector Laboratories). 
For visualization of GFP expression after Cre-recombination, ThIRESCre mice were 
mated wih Z/EG reporter mice (254). Double heterozygous ThIRESCre-Z/EG reporter mice 
were anesthetized and transcardially perfused with physiologic saline solution followed by 
4% paraformaldehyde. Brains were dissected and post-fixed in 4% PFA at 4°C, transferred to 
20% sucrose for 6 h and frozen in tissue freezing medium. Then, 25 µm thick free-floating 
coronal sections were cut through the ventral tegmental area using a freezing microtome 
(Leica). The sections were washed, pretreated with 0.3% H2O2, blocked with PBT/azide 
containing 3% donkey serum, and incubated overnight with primary antibody (anti-GFP 
rabbit serum, 1:10.000 in blocking solution; A6455 from Invitrogen/Molecular Probes). 
Incubation with secondary antibody (anti-rabbit IgG biotin, 1:500; 711-065-152 from Jackson 
ImmunoResearch) was followed by an additional incubation with the VECTASTAIN Elite 
ABC kit (Vector Laboratories) for 1 h and visualization with 0.4% DAB/0.01% H2O2. 
Afterwards the sections were mounted onto gelatin-coated slides and covered with glycerin 
and processed as previously described (255). 
 
For determination of the functional effects of neuron-restricted insulin receptor 
deficiency IR∆POMC, IR∆AgRP as well as IR∆Th mice were mated with LacZ reporter mice (253). 
IR∆POMC/LacZ, IR∆AgRP/LacZ, IR∆Th/LacZ and wildtype reporter (PomcCre-, AgRPCre-, ThIRESCre-
LacZ) mice were starved over night, anesthetized, and intravenously injected with either 
saline or 5U of human regular insulin (NovoNordisc) for 10 min. Mice were then perfused 
transcardially with physiologic saline solution; brains were dissected, frozen in tissue freezing 
medium (Jung Tissue Freezing MediumTM) and sectioned on a cryostat (7 µm). Tissues were 
stained with galactosidase (# 55976; Cappel) and PIP3 (# Z-G345; Echelon, FITC) and 
double fluorescence immunostaining was performed as previously described (202). 
Slides were viewed through a Zeiss Axioskop equipped with a Zeiss AxioCam for 
acquisition of digital images using Spot Advanced 3.0.3 software. 
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2.3.1.2  Analysis of PIP3 formation in situ 
For quantitative analysis of PIP3 levels in POMC neurons, a total of 1812 LacZ-
positive neurons was counted in ARC slices of control mice injected with NaCl, (n = 3; 365 
POMC neurons), insulin-stimulated control mice (n = 4, 532 POMC neurons), IR∆POMC mice 
injected with NaCl (n = 3; 423 POMC neurons) and insulin-stimulated IR∆POMC mice (n = 3, 
492 POMC-neurons). For quantitative analysis of PIP3 levels in AgRP neurons, a total of 673 
LacZ-positive neurons was counted in ARC slices of control mice injected with NaCl, (n = 2; 
75 AgRP neurons), insulin-stimulated control mice (n = 2, 57 AgRP neurons), IR∆AgRP mice 
injected with NaCl (n = 1; 95 AgRP-neurons) and insulin-stimulated IR∆AgRP mice (n = 4, 446 
AgRP-neurons). For quantitative analysis of PIP3 levels in Th-expressing neurons, a total of 
531 LacZ-positive neurons was counted in VTA/SN slices of control mice injected with NaCl, 
(n = 2; 128 Th-expressing neurons), insulin-stimulated control mice (n = 3, 179 Th-expressing 
neurons), IR∆Th mice injected with NaCl (n = 2; 64 Th-expressing neurons) and insulin-
stimulated IR∆Th mice (n = 4, 160 Th-expressing neurons). 
The amount of PIP3 was classified either as low (immunoreactive cytoplasmatic 
dots/sprinkles in the proximity of the nucleus at background levels, i.e., 6 or fewer dots, no 
cloudy aspect, no confluent areas), moderate (dots/sprinkles at levels above background, i.e., 
more than 6 dots, cloudy aspect), or high (numerous dots/sprinkles, cloudy with confluent 
areas). Slides were viewed through a Zeiss Axioskop equipped with a Zeiss AxioCam for 
acquisition of digital images. Neurons positive for β-gal were counted and marked digitally to 
prevent multiple counts, and PIP3 immunoreactivity was rated as previously described (202) 
using Zeiss AxioVision version 4.2 imaging software. Results were expressed as percentage 
of POMC, AgRP or Th-expressing neurons, which show the respective PIP3 levels.  
 
2.3.2 Histomorphology 
Dissected samples (ovaries, testes) were incubated in fixation solution containing 4% 
(w/v) PFA at 4 °C overnight and embedded in paraffin according to a standard protocol. 7 µm 
sections were mounted onto gelatin-coated slides and hematoxylin/eosin-stained (H&E) 
(Sigma, St. Louis, MO, USA) after deparaffinization. Stained sections were viewed under a 
Zeiss Axiophot and pictures were taken with a digital color camera (Spot Diagnostic 
Instruments, Inc., MI, USA) using Spot Advanced 3.0.3 software. 
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2.3.3 Electrophysiology 
Coronal brain slices (250 - 300 µm) containing the ARC were prepared from 6-week-
old AgRPCre-Z/EG and IR∆AgRP-Z/EG mice. After at least 15 min recovery at 35°C in 
artificial cerebrospinal fluid (aCSF) gassed with 95% O2 and 5% CO2, brain slices were 
transferred to a recording chamber and continuously perfused at 2 - 4 ml/min with gassed 
aCSF. aCSF contained (in mM): 125 NaCl, 21 NaHCO3, 2.5 KCl, 1.2 NaH2PO4, 2 CaCl2, 2 
MgCl2, 10 HEPES (pH 7.4), and 5 glucose. Brain slices were viewed with a Zeiss Axioskop 
fitted with fluorescence and infrared differential interference contrast (IR-DIC) 
videomicroscopy. Fluorescent AgRP-EGFP neurons were identified by epifluorescence and 
patched under IR-DIC optics. Whole-cell current-clamp and voltage-clamp recordings were 
made using an EPC-9 patch-clamp amplifier, as previously described (202, 256). Patch 
pipettes had resistances of 3-5 MΩ when filled with internal solution. For most experiments, 
patch pipettes were filled with internal solution containing (in mM): 128 K-gluconate, 10 
KCl, 10 HEPES (pH 7.3, adjusted with KOH), 0.1 EGTA, 2 MgCl2, 0.3 Na-GTP, and 3 K2-
ATP. The external solution was aCSF in all experiments. Experiments were carried out at 22 - 
25°C. Data were filtered, sampled with Pulse/Pulsefit and software (Heka, Elektronik, 
Germany, version 8.67) and analyzed with Pulsefit and Origin (Microcal, Northhampton, 
MA) software (version 6.0). 
Responses to insulin (200 nM; Sigma) in fluorescently labeled POMC neurons in brain 
slices from 10 week old transgenic mice (PomcCre-Z/EG and IR∆POMC-Z/EG) were assessed 
using standard whole cell patch clamp in the current clamp mode, using Axopatch 200B 
(Molecular Devices, Sunnyvale CA), as previously described (176). Baseline membrane 
potential and action potential firing frequency were determined using Mini Analysis 
(Synaptosoft, Decatur GA). 
 
2.3.4 Electron Microscopy  
After a long-term euglycemic-hyperinsulinemic clamp, 11-week-old C57BL/6 male 
mice from the control group (somatostatin) and the treatment group (somatostatin + insulin) 
were perfused for electron microscopy. Mice were anesthetized and perfused transcardially 
with saline followed by Somogyi-Takagi fixative containg 4% paraformaldehyde and 0.8% 
glutaraldehyde in 0.1 M phosphate buffer. A tissue block containing the ventral tegmental 
area was dissected from each brain. 50 µm thick vibratome sections were cut and thoroughly 
washed in 0.1 M phosphate buffer (PB). To eliminate unbound aldehydes, sections were 
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incubated in 1% sodiumborohydride for 15 min, and then rinsed in PB. Next, sections were 
incubated in rabbit anti-GFP (Molecular Probes Inc., Eugene, OR) (dilution 1:1000 in PB) for 
24 h at room temperature. Subsequently, sections were incubated in biotinylated goat anti-
rabbit immunoglobulin (dilution 1: 250; Vector Laboratories, Burlingame, CA, USA) at room 
temperature. After a thorough wash in PB, sections were placed in avidin-biotin-complex 
(ABC Elite Kit, Vector Labs) for 2 h at room temperature. The tissue-bound peroxidase was 
visualized by a diaminobenzidine reaction. After the immunostaining, the sections were 
osmicated (15 min in 1% osmic acid in PB), and dehydrated in increasing ethanol 
concentrations. During the dehydration, 1% uranyl-acetate was added to the 70% ethanol to 
enhance ultrastructural membrane contrast. Dehydration was followed by flatembedding in 
Araldite. Ultrathin sections were cut on a microtome, collected on Formvar-coated single-slot 
grids and analyzed with a Tecnai 12 Biotwin (FEI Company) electron microscope. The 
quantitative analysis of synapse numbers was performed in a double-blind fashion on electron 
micrographs from mice of different experimental groups. To obtain a complementary measure 
of axo-somatic synaptic number, unbiased for possible changes in synaptic size, the disector 
technique was used (S4). On consecutive 90-nm-thick sections, the average projected height 
of the synapses was determined and about 30% of this value was used as the distance between 
the disectors. On the basis of this calculation, the number of axo-somatic synapses was 
counted from 7 perikaryal profiles in two consecutive serial sections roughly 270 nm apart 
(the "reference" and "look-up" sections) from each tissue block. In order to increase the 
sampling size, the procedure was repeated in such a way that the reference and look-up 
sections were reversed. The numbers of symmetrical, asymmetrical and total contacts were 
collected independently from serial sections. Synapse characterization was performed at 
20,000 magnification, while all quantitative measurements were performed on electron 
micrographs at a magnification of 11,000. Symmetric and asymmetric synapses were counted 
on all selected neurons only if the pre- and/or postsynaptic membrane specializations were 
clearly seen and synaptic vesicles were present in the presynaptic bouton. Asymmetric 
synapses are formed by axons that contain large vesicles and excitatory neurotransmitters (i.e. 
primarily glutamate; excitatory synapses). In contrast, symmetric synapses have presynaptic 
axons with small synaptic vesicles that contain the inhibitory transmitter γ-aminobutyric acid 
(GABA). The presynaptic and postsynaptic densities of these synapses are approximately of 
equal thickness (inhibitory synapses). Synapses with neither clearly symmetric nor 
asymmetric membrane specializations were excluded from the assessment. The plasma 
membranes of selected cells were outlined on photomicrographs and their length was 
                                                                                                                                  Materials and Methods 
 31 
measured with the help of a chartographic wheel. Plasma membrane length values measured 
in the individual animals were added and the total length was corrected to the magnification 
applied. Synaptic densities were evaluated according to the formula NV=Q-/Vdis where Q- 
represents the number of synapses present in the "reference" section that disappeared in the 
"look-up" section. Vdis is the disector volume (volume of reference) which is the area of the 
perikaryal profile multiplied by the distance between the upper faces of the reference and 
look-up sections, i.e. the data are expressed as numbers of synaptic contacts per unit volume 
of perikaryon. Section thickness was determined by using the Small's minimal fold method. 
The synaptic counts were expressed as numbers of synapses on a membrane length unit of 
100 µm. Since an F-test analysis of synaptic counts in the ARC of the mice has revealed a 
significant nonhomogeneity of variances between groups, the Kruskal-Wallis one-way non-
parametric analysis of variance test was selected for multiple statistical comparisons. The 
Mann-Whitney U-test was used to determine significance of differences between the groups. 
A level of confidence of P < 0.05 was employed for statistical significance.  
 
2.4 Biochemistry 
2.4.1 Enzyme-linked Immunosorbent Assay (ELISA) 
Serum insulin and leptin, as well as plasma corticosterone concentrations were 
measured by ELISA according to manufacturer’s guidelines (Mouse Leptin ELISA, 
Mouse/Rat Insulin ELISA, Crystal Chem, Downers Grove, IL, USA; Insulin Mouse 
Ultrasensitive ELISA, DRG Instruments GmbH; Mouse Leptin Immunoassay, Quantikine; 
Corticosterone Enzyme Immunoassay Kit, Assay Designs Inc.). For evaluation of steady state 
clamped insulin serum levels, an ultrasensitive Insulin ELISA for determination of human 
insulin was performed according to manufacturer’s guidelines (Ultrasensitive Insulin ELISA, 
#EIA-2337, DRG Instruments). 
 
2.4.2 Protein Extraction 
Snap-frozen tissues were thawed and homogenized in lysis buffer (50 mM HEPES 
(pH 7.4), 1% Triton X-100, 0.1 M NaF, 10 mM EDTA, 50 mM NaCl, 10 mM Na3O4V, 0.1% 
SDS, 10 µg/ml Aprotinin, 2 mM Benzamidine, 2 mM PMSF) using a polytron homogenizer 
(IKA Werke, Staufen, Germany). Particulate matter was removed by centrifugation for 1 h at 
4°C. The supernatant was transferred to a new vial and protein concentrations were 
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determined by measuring the sample absorption at 280 nm with a NanoDrop ND-1000 UV-
Vis Spectrophotometer (Peqlab, Erlangen, Germany). Proteins that contain Trp, Tyr residues 
or Cys-Cys disulphide bonds absorb in the UV range of 280 nm. Subsequently, protein 
extracts were diluted to 10 mg/ml with lysis buffer and 4 x SDS sample buffer (125 mM Tris-
HCl (pH 6.8), 5% SDS, 43.5% glycerol, 100 mM DTT, and 0.02% bromophenol blue), 
incubated at 95°C for 5 min and stored at -80°C.  
 
2.4.3 Western Blot Analysis 
Frozen protein extracts were thawed at 95°C for 5 min, then separated on 8 - 10% 
(v/v) SDS polyacrylamide gels and blotted onto PVDF membranes (Bio-Rad, München, 
Germany). Membranes were then incubated with 1% blocking reagent (Roche, Mannheim, 
Germany) for 1 h at RT or overnight at 4°C. Subsequently, primary antibodies (Table 5) 
diluted in 0.5% blocking solution were applied for 1 h at RT or overnight at 4°C. PVDF 
membranes were then washed twice for 10 min with 1 x TBS/Tween and incubated twice for 
10 min with 0.5% blocking solution. After 1 h incubation at RT with the respective secondary 
antibodies, membranes were washed 4 times for 5 min with 1 x TBS/Tween, incubated for 1 
min in Pierce ECL Western Blotting Substrate (Perbio Science, Bonn, Germany), sealed in a 
plastic bag and exposed to chemiluminescence films (Amersham, Braunschweig, Germany). 
Films were developed in an automatic developer. 
 
Table 5: Primary antibodies used for Western blot analysis. 
Antibody Catalogue N° Distributor Dilution 
β-Actin #A5441 Sigma Aldrich, Seelze, Germany 1:5000 
α-Tubulin #T6074 Sigma Aldrich, Seelze, Germany 1:5000 
Akt #4685 Cell Signaling, Danvers, MA, USA 1:1000 
G6Pase-α sc-25840 Santa Cruz, Heidelberg, Germany 1:200 
IRβ (C-19) sc-711 Santa Cruz, Heidelberg, Germany 1:200 
pAkt  #4056 Cell Signaling, Danvers, MA, USA 1:1000 
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2.5 Mouse Experiments 
General animal handling was performed as described by Hogan (257) and Silver 
(258). 
 
2.5.1 Animal Care 
All animal procedures and euthanasia were reviewed by the animal care committee of 
the University of Cologne, approved by local government authorities (Bezirksregierung Köln) 
and were in accordance with National Institutes of Health guidelines. Mice were housed in 
groups of 3 to 5 or individually if required for an experiment as indicated. Mice were housed 
in a virus-free facility at 22 - 24°C on a 12 h light / 12 h dark cycle with the light on at 7 a.m. 
and were either fed a normal chow diet (Teklad Global Rodent # T.2018.R12; Harlan, 
Borchen, Germany) containing 53.5 % of carbohydrates, 18.5 % of protein, and 5.5 % of fat 
(12 % of calories from fat) or a high fat containing diet (# C1057; Altromin, Lage, Germany) 
containing 32.7 %, 20 % and 35.5 % of carbohydrates, protein and fat (55.2 % of calories 
from fat), respectively. All animals had access to water ad libitum. Food was only withdrawn 
if required for an experiment. At the end of the study period, animals were sacrificed by CO2 
anesthesia or cervical dislocation. Body weight was measured once a week.  
 
2.5.2 Mice 
AgRPCre (259, 260) and PomcCre mice (182) were mated with IRlox/lox mice (58), and 
breeding colonies were maintained by mating IRlox/lox with AgRPCre-IRlox/lox (IR∆AgRP) and 
PomcCre-IRlox/lox (IR∆POMC) mice, respectively. IRlox/lox mice had been backcrossed for at least 
5 generations on a C57BL/6 background, and AgRPCre and PomcCre mice – initially 
established on a FVB background – had been backcrossed for 2 generations on a C57BL/6 
background before intercrossing them with IRlox/lox mice. ThIRESCre mice (261) were mated 
with IRlox/lox mice, and breeding colonies were maintained by mating IRlox/lox with ThIRESCre-
IRlox/lox (IR∆Th). Only animals from the same mixed background strain generation were 
compared to each other. Mice were genotyped by PCR using genomic DNA isolated from tail 
tips. Germline deletion was excluded within the IRlox/lox PCR using three primers, one binding 
upstream the first loxP site and the others flanking the second loxP site.  
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2.5.3 Collection of Blood Samples and Determination of Blood Glucose Levels 
Tail bleeding of mice was performed according to Hogan (257) and Silver (258). 
Blood glucose values were determined from whole venous blood using an automatic glucose 
monitor (GlucoMen® GlycÓ; A. Menarini Diagnostics, Florence, Italy). Determination of 
blood glucose levels and collection of blood samples were performed in the morning to avoid 
deviations due to circadian variations.  
 
2.5.4 Food Intake and Indirect Calorimetry 
Food intake was measured over a two-week period, during which mice were housed 
individually in regular cages using food racks. To minimize handling of the animals, food 
racks were weighed every second day and daily food intake was calculated as the average 
daily intake of chow within the time stated. Indirect calorimetry was measured in a 
Calorimetry Module (CaloSys V2.1, TSE Systems, Bad Homburg, Germany and CLAMS, 
Oximax Windows 4.00, Columbus Instruments, Columbus, OH, USA). After two hours of 
acclimatization, parameters of indirect calorimetry were measured for at least 48 h. For the 
measurement of physical activity, transmitters (PDT-4000 E-Mitter, VitalView Data 
Acquisition System 4.1; Mini Mitter, Bend, OR, USA) were implanted into the peritoneal 
cavity of Avertin-anesthetized mice. After 7 days mice that reached at least 90 % of their 
preoperative body weight were placed into 3.0 l chambers of a Comprehensive Laboratory 
Animal Monitoring System (CLAMS, Oximax Windows 4.00, Columbus Instruments, 
Columbus, OH, USA). Food and water were provided ad libitum for the measurement of 
basal locomotor activity. Mice were allowed to acclimatize in the chambers for 2 h. Physical 
activity was measured for at least the following 48 h.  
 
2.5.5 Glucose and Insulin Tolerance Test 
Glucose tolerance tests (GTT) were performed on animals that had been fasted 
overnight for 16 hours. Insulin tolerance tests (ITT) were performed on random fed mice. 
Animals were injected with 2 g/kg body weight of glucose or 0.75 U/kg body weight of 
human regular insulin into the peritoneal cavity, respectively. Glucose levels were determined 
in blood collected from the tail tip immediately before and 15, 30 and 60 minutes after the 
injection, with an additional value determined after 120 minutes for the GTT. 
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2.5.6 Insulin Signaling 
Mice were anesthetized by intraperitoneal (ip) injection of avertin and adequacy of the 
anesthesia was ensured by loss of pedal reflexes. The abdominal cavity of the mice was 
opened and 125 µl samples containing 5U regular human insulin diluted in 0.9% saline were 
injected into the Vena cava inferior. Sham injections were performed with 125 µl of 0.9% 
saline. Samples of liver tissue and skeletal muscle tissue were harvested two and five minutes 
after injection, respectively, and proteins were extracted from tissues for Western blot 
analysis. 
 
2.5.7 Analysis of Body Composition 
Nuclear magnetic resonance (NMR) was employed to determine whole body 
composition of live animals using the NMR Analyzer minispec mq7.5 (Bruker Optik, 
Ettlingen, Germany). Radiofrequency (RF) pulse sequences are transmitted into the tissue. In 
response, RF signals are generated by the hydrogen in the tissues, which are detected by the 
minispec. The amplitude and duration of these signals are related to properties of the material.  
 
2.5.8 Fertility Assessment 
IRlox/lox (control), IR∆POMC, IR∆AgRP and IR∆Th females were bred with IR∆POMC, 
IR∆AgRP, IR∆Th or IRlox/lox (control) males, respectively. Mean litter size and litter intervals 
were assessed over a period of at least three litters. For histological examination, ovaries and 
testes of 15 weeks old animals were dissected, fixed overnight in 4% formaldehyde and then 
embedded for paraffin sections. Subsequently, 7µm thick sections were deparaffinized and 
stained using haematoxylin and eosin (H&E) for general histology. 
 
2.5.9 Restraint Stress 
Mice were familiarized with gentle handling for approximately 8 weeks prior to the 
experiment. For determination of basal serum corticosterone levels, blood was drawn from the 
tail vein during the first 3 h of the light phase. The following day, mice were subjected to 1 h 
of restraint stress at the same time of the light phase. Restraint stress was achieved by 
enclosing the animals in a plastic tube with a diameter of 3 cm and openings at both ends for 
tail and nose. The length of the tube was adjusted to the size of the animal to ensure complete 
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immobilization. At the end of the experiment, blood samples were collected from the tail 
vein. 
 
2.5.10 Euglycemic-Hyperinsulinemic Clamp Studies in Awake Mice 
2.5.10.1 Catheter Implantation 
At the age of 14 weeks, male mice were anesthetized by ip injection of avertin (240 
mg/kg) (2,2,2-tribromoethanol) and adequacy of the anesthesia was ensured by the loss of 
pedal reflexes. A Micro-Renathane catheter (MRE 025; Braintree Scientific Inc.) was inserted 
into the right internal jugular vein, advanced to the level of the superior vena cava, and 
secured in its position in the proximal part of the vein with 4-0 silk; the distal part of the vein 
was occluded with 4-0 silk. After irrigation with physiological saline solution, the catheter 
was filled with heparin solution and sealed at its distal end. The catheter was subcutaneously 
tunneled, thereby forming a subcutaneous loop, and exteriorized at the back of the neck. 
Cutaneous incisions were closed with a 4-0 silk suture and the free end of the catheter was 
attached to the suture in the neck as to permit the retrieval of the catheter on the day of the 
experiment. Mice were intraperitoneally injected with 1 ml of saline containing 15µg/g body 
weight of tramadol and placed on a heating pad in order to facilitate recovery. 
 
2.5.10.2 Radioactive Euglycemic-Hyperinsulinemic Clamp Experiment 
Only mice that had regained at least 90% of their preoperative body weight after 6 
days of recovery were included in the experimental groups. After starvation for 16 h, awake 
animals were placed in restrainers for the duration of the clamp experiment. After a D-[3-3H] 
Glucose tracer solution bolus infusion (5µCi), the tracer was infused continuously 
(0.05µCi/min) for the duration of the experiment. At the end of the 40-minute basal period, a 
blood sample (50µl) was collected for determination of the basal parameters. To minimize 
blood loss, red blood cells were collected by centrifugation and reinfused after being 
resuspended in saline. Insulin solution containing 0.1% BSA was infused at a fixed rate 
(4µU/g/min) following a bolus infusion (40µU/g). Blood glucose levels were determined 
every 10 minutes (B-Glucose Analyzer; Hemocue) and physiological blood glucose levels 
(between 120 and 145 mg/dl) were maintained by adjusting a 20% glucose infusion to prevent 
a counterregulatory response to hypoglycemia. Approximately 120 minutes before steady 
state was achieved, a bolus of 2-Deoxy-D-[1-14C] Glucose (10µCi) was infused. Steady state 
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was ascertained when glucose measurements were constant for at least 30 min at a fixed 
glucose infusion rate. During the clamp experiment, blood samples (5µl) were collected after 
the infusion of the 2-Deoxy-D-[1-14C] Glucose at time points 0, 5, 15, 25, 35 min etc. until 
reaching the steady state. During the steady state, blood samples (50µl) for the measurement 
of steady state parameters were collected. At the end of the experiment, mice were sacrificed 
by cervical dislocation, and brain, liver, white adipose tissue and skeletal muscle were 
dissected and stored at -80°C. 
 
2.5.10.2.1 Assays 
Plasma [3-3H] Glucose radioactivity of basal and steady state control-, IRΔAgRP- and 
IRΔPomc samples was determined directly after deproteinization with 0.3M Ba(OH)2 and 0.3M 
ZnSO4 and after removal of 3H2O by evaporation, using a liquid scintillation counter 
(Beckmann). Plasma Deoxy-[1-14C] Glucose radioactivity was directly measured in the liquid 
scintillation counter. White adipose tissue, skeletal muscle and brain lysates were processed 
by using Ion exchange chromatography columns (Poly-Prep® Prefilled Chromatography 
Columns, AG®1-X8 formate resin, 200-400 mesh dry; Bio Rad Laboratories) to separate 2-
Deoxy-D-[1-14C] Glucose (2DG) from 2-Deoxy-D-[1-14C] Glucose-6-Phosphate (2DG6P).  
For determination of basal G6Pase-α protein and IL-6 mRNA expression, 16 h fasted 
animals were dissected and livers were stored at -80°C until further preparation. Basal and 
steady state liver samples were processed for Western blot analysis as well as for Realtime 
PCR. 200 ng of each total RNA sample was reverse-transcribed, then PCR-amplified using 
TaqMan® Principles ABI Prism 7700 Sequence Detection System.  
 
2.5.10.2.2 Calculations 
Glucose turnover rate (mg × kg-1× min-1) was calculated as the rate of tracer infusion 
(dpm/min) divided by the plasma glucose-specific activity (dpm/mg) corrected for body 
weight. Hepatic glucose production (mg × kg-1× min-1) was calculated as the difference 
between the rate of glucose appearance and glucose infusion rate. In vivo glucose uptake for 
white adipose tissue, brain, and skeletal muscle (nmol × g-1× min-1) was calculated based on 
the accumulation of 2DG6P in the respective tissue and the disappearance rate of 2DG from 
plasma as described previously (262). 
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2.5.10.3 Long-term euglycemic-hyperinsulinemic clamp experiment 
Only 11-week-old C57BL/6 male mice that had regained at least 90% of their 
preoperative body weight after 6 days of recovery were included in the experimental groups. 
After starvation for 18 h, awake animals were placed in restrainers for the duration of the 
clamp experiment. After collection of a blood sample (100µl) for determination of basal 
parameters, mice received a continuous intravenous infusion of somatostatin (3µg/kg/min) 
(control group) to inhibit endogenous insulin and glucagon release or continuous intravenous 
infusion of somatostatin (3µg/kg/min) and insulin (4µU/g/min) (treatment group). Blood 
glucose levels were determined every 20 minutes (B-Glucose Analyzer; Hemocue) and 
physiological blood glucose levels (between 100 and 145 mg/dl) were maintained by 
adjusting a 20% glucose infusion in both groups. At the end of the experiment (after 6 h) and 
collection of a blood sample, mice were perfused for electron microscopy. 
 
2.6 Computer Analysis 
2.6.1 Densitometrical Analysis 
Protein expression was assessed by Western blot analysis and bands were measured in 
intensity per mm2 using the Quantity One Software (Bio-Rad, München, Germany). After 
background subtraction, each sample was normalized to an internal loading control. Average 
protein expression of control mice was set to 100% and compared to protein expression of 
knockout animals unless stated otherwise. 
 
2.6.2 Statistical Methods 
Data sets were analyzed for statistical significance using a two-tailed unpaired 
student’s t test. All p values below 0.05 were considered significant. All displayed values are 
means ± SEM. * p ≤ 0.05 ; ** p ≤ 0.01 ; *** p ≤ 0.001 versus controls.  
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3 Results 
 
3.1 Generation of POMC and AgRP neuron-specific insulin receptor 
knockout mice 
To investigate the role of insulin signaling in POMC- and/or AgRP-expressing 
neurons, the insulin receptor gene was inactivated specifically in each of these cells. To this 
end, mice expressing a Cre recombinase under control of either the Pomc- or the AgRP-
promoter (182, 259, 260) were crossed with mice carrying a loxP-flanked insulin receptor 
gene (IRlox/lox) (Figure 5) (58).  
 
 
Figure 5: POMC and AgRP neuron-restricted inactivation of the insulin receptor gene. 
(A) Map of the loxP-flanked insulin receptor gene exon 4. LoxP sites were introduced 2 kb upstream and 80 bp 
downstream of exon 4. Cre mediated recombination of this allele will lead to deletion of exon 4 and splicing of 
exon 3 and 5, and is predicted to cause a frameshift mutation resulting in a stop of translation. Each loxP site is 
here and hereafter depicted as a triangle. (B) Map of the PomcCre transgene. Mice expressing Cre recombinase 
(Cre) under Pomc promoter control were generated by engineering a Pomc bacterial artificial chromosome. The 
Cre translational initiation site (ATG) was inserted into the Pomc ATG and deleted the first 30 bp of the Pomc 
gene. (C) Map of the AgRPCre transgene. Mice expressing Cre recombinase (Cre) under AgRP promoter control 
were generated by engineering an AgRP bacterial artificial chromosome. The CreIVSpA cassette is targeted 
precisely upstream of the normal AgRP translational initiation site (ATG) in exon 2.  
 
 
 
A
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In IRlox/lox mice, harboring the PomcCre or the AgRPCre recombinase transgene, the 
loxP-flanked insulin receptor gene is selectively removed upon Cre-mediated recombination, 
leading to the inactivation of the insulin receptor selectively in POMC or AgRP neurons, 
respectively (Figure 6). 
 
 
Figure 6: General scheme of mice with POMC (IRΔPOMC) and AgRP (IRΔAgRP) neuron-restricted 
inactivation of the insulin receptor gene. 
(A) Mice, homozygous for a loxP-flanked exon 4 of the insulin receptor allele (IRlox/lox) were crossed with mice 
expressing the Cre protein under the control of the Pomc promoter. Only one loxP-flanked allele is depicted 
here. (B) Mice, homozygous for a loxP-flanked exon 4 of the insulin receptor allele (IRlox/lox) were crossed with 
mice expressing the Cre protein under the control of the AgRP promoter. Only one loxP-flanked allele is 
depicted here.  
 
To analyze cell type-specific inactivation of the insulin receptor, Cre-mediated 
recombination was visualized by crossing PomcCre as well as AgRPCre mice to a reporter 
mouse strain in which transcription of the β-galactosidase gene (LacZ) under control of the 
ubiquitously expressed Rosa26 promoter is prevented by a floxed hygromycin resistance gene 
(LacZ reporter mice), thus leading to β-galactosidase expression only in cells expressing the 
Cre recombinase (Figure 7 A) (253). These mice showed a pattern of LacZ immunoreactivity 
in the ARC of the hypothalamus reflecting the described expression pattern of endogenously 
expressed POMC and AgRP (Figure 7 B, C), consistent with the previously demonstrated 
colocalization of endogenous POMC/AgRP expression and Cre recombinase activity (182, 
259, 260). 
 
 
 
A
B
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Figure 7: Verification of Cre-mediated recombination in PomcCre and AgRPCre mice. 
(A) Map of the LacZ transgene for Cre-mediated expression from the Rosa26 locus. pGK-hyg: hygromycin 
resistance gene driven by the pGK (phosphoglycerate kinase) promoter. In this configuration Cre-mediated 
recombination removes the loxP-flanked hygromycin resistance gene only in cell types expressing Cre 
recombinase, resulting in transcription of β-galactosidase (β-gal). (B) Immunohistochemistry for β-gal in brains 
of double heterozygous reporter mice (LacZ+/- PomcCre) at the age of ten weeks. Blue (DAPI), DNA; green, β-
gal (POMC neurons). Scale bar 100µm. (C) Immunohistochemistry for β-gal in brains of double heterozygous 
reporter mice (LacZ+/- AgRPCre) at the age of ten weeks. Blue (DAPI), DNA; green, β-gal (AgRP neurons). 
Scale bar 100µm. 
 
 
To confirm the specificity of insulin receptor inactivation, Western blot analyses were 
performed on tissue lysates obtained from mice with specific insulin receptor inactivation in 
POMC (IRΔPOMC) and AgRP (IRΔAgRP) neurons. Consistent with restricted inactivation of the 
insulin receptor in defined subpopulations of hypothalamic neurons, Western blot analysis 
revealed no alterations in overall brain and hypothalamic insulin receptor protein expression 
(Figure 8). Similarly, insulin receptor expression in peripheral tissues, including liver, skeletal 
muscle and pancreas remained unchanged in IRΔPOMC and IRΔAgRP mice (Figure 8).  
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Figure 8: Western blot analysis of insulin receptor expression. 
Western blot analysis of insulin receptor β subunit (IR), protein kinase B (Akt) (loading control) and α-Tubulin 
(loading control). Proteins were extracted from whole brain, hypothalamus, liver, skeletal muscle and pancreas 
of control, IRΔPOMC and IRΔAgRP mice. 
 
Next, insulin’s ability to activate signaling in skeletal muscle and liver of control, 
IRΔPOMC and IRΔAgRP mice was assessed. Consistent with restricted inactivation of the insulin 
receptor, insulin-stimulated Akt-phosphorylation occurred normally in liver and skeletal 
muscle of IRΔPOMC and IRΔAgRP mice as compared to controls (Figure 9). 
 
Figure 9: Insulin signaling in peripheral organs of control, IRΔPOMC and IRΔAgRP mice. 
Western blot analysis of protein kinase B (Akt), phosphorylated Akt and α-Tubulin (loading control) in liver and 
skeletal muscle (skel. muscle) of control, IRΔPOMC and IRΔAgRP mice after injection of either saline (-) or insulin 
(+) into the Vena cava inferior. 
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Consistent with the expression pattern of endogenously expressed POMC, the only 
non-hypothalamic site of recombination detectable in PomcCre transgenic mice was the 
pituitary (255). However, this did not have any effect on the response to stress of IR∆POMC 
mice assessed by measurement of stress-induced plasma corticosterone levels (Figure 10). 
Restraint-stress induced increases in plasma corticosterone concentrations were similar in 
control and IR∆POMC mice (Figure 10), indicating that insulin receptor expression is not 
required for the development, maintenance or normal function of anterior pituitary 
corticotrope cells.  
 
 
Figure 10: Regulation of the hypothalamic-pituitary-adrenal axis in IRΔPOMC mice. 
Basal and stress-induced plasma corticosterone levels in 12-week-old male control (n = 7) and IRΔPOMC (n = 10) 
mice. Displayed values are means ± S.E.M.; **, p ≤ 0.01. 
 
 
Since mice with a neuron-specific insulin receptor knockout (NIRKO) exhibit 
hypogonadism (58), parameters of fertility were assessed in IRΔPOMC and IRΔAgRP mice. This 
revealed no significant differences concerning litter-to-litter intervals, litter size and 
morphology of reproductive organs between control, IRΔPOMC and IRΔAgRP mice, indicating 
that insulin signaling in these neurons is not required for control of fertility (Figure 11). 
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Figure 11: Fertility of IRΔPOMC and IRΔAgRP mice. 
(A) Mean litter intervals for control, IRΔPOMC and IRΔAgRP mice assessed over a period of at least three litters (n = 
3 breedings). (B) Mean litter size for control, IRΔPOMC and IRΔAgRP mice assessed over a period of at least three 
litters (n = 3 breedings). (C) Representative hematoxylin/eosin staining of ovaries and testes from control, 
IRΔPOMC and IRΔAgRP mice. Scale bar 100µm. Displayed values are means ± S.E.M.. 
 
Next, functional effects of POMC and AgRP neuron-restricted insulin receptor 
deficiency on insulin’s ability to activate the PI3 kinase pathway in control, IRΔPOMC and 
IRΔAgRP LacZ reporter mice were determined. To this end, overnight fasted mice were 
intravenously injected with either saline or insulin and sacrificed 10 min afterwards. 
Following, phosphatidylinositol (3,4,5) trisphosphate (PIP3) formation was analyzed by 
immunohistochemistry in hypothalamic slices (Figure 12). 
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Figure 12: PIP3 formation in hypothalamic neurons of control, IR∆POMC and IR∆AgRP reporter mice. 
(A) Double immunohistochemistry of ARC neurons of control and IRΔPOMC reporter mice was performed in 
overnight fasted mice, which were intravenously injected with either saline or insulin and sacrificed 10 min 
afterwards. Arrows indicate 1 POMC and 1 non-POMC neuron in each panel. (B) Quantification of PIP3 levels 
in control reporter mice in the basal state (-) and after insulin (+) stimulation. Values are means ± S.E.M. of 
sections obtained from 3 unstimulated and 4 insulin-stimulated control mice. **, p ≤ 0.01. (C) Quantification of 
PIP3 levels in IRΔPOMC reporter mice in the basal state (-) and after insulin (+) stimulation. Values are means ± 
S.E.M. of sections obtained from 3 unstimulated and 3 insulin-stimulated IRΔPOMC mice. (D) Double 
immunohistochemistry of ARC neurons of control and IRΔAgRP reporter mice was performed in overnight fasted 
mice, which were intravenously injected with either saline or insulin and sacrificed 10 min afterwards. Arrows 
indicate 1 AgRP and 1 non-AgRP neuron in each panel. (E) Quantification of PIP3 levels in control reporter 
mice in the basal state (-) and after insulin (+) stimulation. Values are means ± S.E.M. of sections obtained from 
2 unstimulated and 2 insulin-stimulated control mice. *, p ≤ 0.05. (F) Quantification of PIP3 levels in IRΔAgRP 
reporter mice in the basal state (-) and after insulin (+) stimulation. Values are means ± S.E.M. of sections 
obtained from 1 unstimulated and 4 insulin-stimulated IRΔAgRP mice. (G) Examples of different magnitudes of 
PIP3 immunoreactivity as described in the Materials & Methods section. Blue (DAPI), DNA; red, β-gal (AgRP 
or POMC neurons); green, PIP3. 
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In the basal state, little immunoreactive PIP3 was detectable in POMC, AgRP and 
adjacent neurons of control, IR∆POMC and IR∆AgRP reporter mice (Figure 12). In control mice, 
insulin treatment resulted in profound activation of PIP3 formation in POMC-, AgRP- and 
non-POMC- or non-AgRP-expressing neurons of the ARC (Figure 12). In contrast, in 
IR∆POMC and IR∆AgRP mice insulin stimulation resulted in PIP3 formation in non-POMC or 
non-AgRP cells, but it failed to activate PIP3 formation in POMC and AgRP neurons (Figure 
12). These data indicate efficient and specific insulin receptor inactivation in POMC cells of 
IR∆POMC mice and AgRP cells of IR∆AgRP mice.  
 
Taken together, these data demonstrate an efficient inactivation of the insulin receptor 
gene in POMC and AgRP neurons of the hypothalamus, while functional signaling in the 
periphery, fertility, and regulation of the hypothalamic-pituitary-adrenal axis are unaltered in 
these mice. 
 
3.2  Insulin hyperpolarizes AgRP and POMC neurons via KATP channel 
activation 
Insulin has previously been shown to reduce the electrical activity of unidentified 
hypothalamic neurons (263) as well as identified POMC neurons (202), via activation of KATP 
channels; whereas blockade of central KATP channels abrogates insulin’s ability to inhibit 
hepatic glucose production (47, 264). Therefore, insulin’s ability to modulate membrane 
potential and action potential frequency in POMC and AgRP neurons of control, IR∆POMC and 
IR∆AgRP mice was examined using the reporter mouse strain LacZ/EGFP (Z/EG), which 
carries a transgene comprising a loxP-flanked β-galactosidase/neomycin-resistance (βgeo) 
fusion gene followed by the coding sequence of the enhanced green fluorescent protein 
(EGFP) (254). In this configuration, EGFP (herein after referred to as GFP) is expressed only 
in cells expressing Cre recombinase (Figure 13). 
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Figure 13: Z/EG expression construct. 
Map of the Z/EG expression construct: The Z/EG transgene consists of the strong pCAGGS (chicken β actin 
promoter with upstream CMV enhancer) promoter, directing expression of a loxP-flanked βgeo (lacZ/neomycin-
resistance) fusion gene and three SV40 polyadenylation sequences (3xpA). Following that is the coding 
sequence of the enhanced green fluorescent protein (EGFP) and a rabbit β globin polyadenylation sequence 
(pA). In this configuration, βgeo is expressed before Cre excision and EGFP is expressed after Cre excision. 
 
 
 
Consistent with previous reports (202), insulin caused membrane hyperpolarization 
and reduced the firing frequency of identified POMC neurons in control mice (Figure 14). In 
contrast, insulin had no effect on POMC neurons of IR∆POMC mice, while basal firing rate 
appeared to be lower in these cells.  
 
Taken together, these data demonstrate the efficiency of insulin receptor inactivation 
in IR∆POMC mice and show that insulin stimulates POMC neuron hyperpolarization by direct 
interaction with insulin receptors on POMC neurons. 
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Figure 14: Effects of insulin on electrical activity of control and IRΔPOMC-Z/EG neurons. 
(A) Representative membrane potential recordings of identified POMC neurons in ARC slices from PomcCre-
Z/EG (control) and IRΔPOMC-Z/EG mice before and after addition of 200 nM insulin. (B) Mean membrane 
potential of identified POMC neurons in ARC slices from PomcCre-Z/EG (n = 4) and IRΔPOMC-Z/EG (n = 6) 
mice before (-) and after (+) addition of 200 nM insulin. (C) Mean firing frequency of PomcCre-Z/EG (n = 4) 
and IRΔPOMC-Z/EG (n = 6) neurons before (-) and after (+) addition of 200 nM insulin. Displayed values are 
means ± S.E.M.; **, p ≤ 0.01. 
 
Next, similar experiments were performed in identified AgRP neurons of control and 
IR∆AgRP mice. Insulin hyperpolarized AgRP cells of control mice and reduced their action 
potential frequency (Figure 15), which is consistent with the finding that AgRP cells also 
express KATP channels (265). In contrast, insulin failed to alter either membrane potential or 
action potential frequency in all AgRP neurons tested from IR∆AgRP mice (Figure 15), 
indicating that the insulin-induced hyperpolarization and changes in action potential 
frequency of AgRP neurons are directly mediated by the insulin receptors on these cells. 
Thus, abrogation of insulin signaling had been successfully achieved in AgRP cells of IR∆AgRP 
mice. Additionally, the effect of the KATP channel blocker tolbutamide was analyzed in these 
cells. Application of tolbutamide reversed the insulin-induced hyperpolarization in identified 
AgRP cells of control mice; consistent with the finding that inactivation of POMC neurons by 
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insulin occurs via KATP channel activation (202) (Figure 15). Thus, these findings indicate that 
the same mechanism reported for POMC neurons also holds true for AgRP neurons. 
 
 
Figure 15: Effects of insulin and tolbutamide on electrical activity of control and IRΔAgRP-Z/EG neurons. 
(A) Representative membrane potential recordings of identified AgRP neurons in ARC slices from AgRPCre-
Z/EG (control) and IRΔAgRP-Z/EG mice before and after addition of 200 nM insulin. (B) Mean membrane 
potential of identified AgRP neurons in ARC slices from AgRPCre-Z/EG (n = 6) and IRΔAgRP-Z/EG (n = 6) mice 
before (-) and after (+) addition of 200 nM insulin. (C) Mean firing frequency of AgRPCre-Z/EG (n = 6) and 
IRΔAgRP-Z/EG (n = 6) neurons before (-) and after (+) addition of 200 nM insulin (control vs. IRΔAgRP before 
addition of insulin p = 0.11). (D) Representative membrane potential recording of an identified AgRP neuron in 
an ARC slice from an AgRPCre-Z/EG (control) mouse before and after addition of 200 nM insulin, and addition 
of 200 µM tolbutamide. Displayed values are means ± S.E.M. ***, p ≤ 0.001. 
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3.3  Normal body weight and energy homeostasis in IR∆AgRP and IR∆POMC 
mice 
To determine the importance of insulin receptor signaling in POMC and AgRP cells 
on the regulation of energy homeostasis, body weight of control (IRlox/lox), IR∆POMC and 
IR∆AgRP mice was monitored from weaning until 4 months of age. This revealed no 
differences in body weight between the three types of male mice on normal diet (Figure 16 A, 
B) and all three genotypes responded to high fat diet with similar increases in body weight 
(Figure 16 C, D).  
 
Figure 16: Body weight of IRΔPOMC and IRΔAgRP mice. 
(A) Average body weight of male control () and IRΔPOMC () mice on normal diet (ND) (n = 26 - 31). (B) 
Average body weight of male control () and IRΔAgRP () mice on normal diet (ND) (n = 18 - 25). (C) Average 
body weight of male control () and IRΔPOMC () mice on high fat diet (HFD) (n = 7 - 12). (D) Average body 
weight of male control () and IRΔAgRP () mice on high fat diet (HFD) (n = 16 - 22). Displayed values are 
means ± S.E.M.. 
 
Consistent with these findings, circulating serum leptin concentrations were indistinguishable 
between control, IR∆POMC and IR∆AgRP mice on normal diet and all increased to the same 
extent under high fat diet conditions (Figure 17). 
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Figure 17: Serum leptin concentrations in IRΔPOMC and IRΔAgRP mice. 
(A) Serum leptin levels of male control (n = 10) and IRΔPOMC (n = 10) mice on normal (ND) and high fat diet 
(HFD) at the age of 15 weeks. (B) Serum leptin levels of male control (n = 11 - 15) and IRΔAgRP (n = 8 - 15) mice 
on normal (ND) and high fat diet (HFD) at the age of 15 weeks. Displayed values are means ± S.E.M.. 
 
Furthermore, daily food intake was measured and compared between control, IR∆POMC 
and IR∆AgRP mice. Consistent with unaltered body weight in these mice, both IR∆POMC and 
IR∆AgRP showed a food intake comparable to control mice (Figure 18).  
 
 
Figure 18: Daily food intake of IRΔPOMC and IRΔAgRP mice. 
(A) Daily food intake of male control (n = 15) and IRΔPOMC (n = 20) mice on normal diet at the age of 11 - 13 
weeks. (B) Daily food intake of male control (n = 11) and IRΔAgRP (n = 11) mice on normal diet at the age of 11 - 
13 weeks. Displayed values are means ± S.E.M.. 
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Next, parameters of energy homeostasis were investigated in female control, IR∆POMC 
and IR∆AgRP mice. Body weight, serum leptin concentrations and food intake were also 
unaltered in female mice both on normal and high fat diet (Figure 19).  
 
Figure 19: Body weight, leptin levels and food intake of IRΔPOMC and IRΔAgRP female mice. 
(A) Average body weight of female control () and IRΔPOMC () mice on normal diet (ND) (n = 10 - 16). (B) 
Average body weight of female control () and IRΔAgRP () mice on normal diet (ND) (n = 16 - 25). (C) Serum 
leptin levels of female control (n = 7 - 10) and IRΔPOMC (n = 10) mice on normal diet (ND) and high fat diet 
(HFD) at the age of 15 weeks. (D) Serum leptin levels of female control (n = 5 - 15) and IRΔAgRP (n = 10 - 15) 
mice on normal diet (ND) and high fat diet (HFD) at the age of 15 weeks. (E) Daily food intake of female 
control (n = 11) and IRΔPOMC (n = 10) mice on normal diet at the age of 11-13 weeks. (F) Daily food intake of 
female control (n = 15) and IRΔAgRP (n = 12) mice on normal diet at the age of 11 - 13 weeks. (G) Average body 
weight of female control () and IRΔPOMC () mice on high fat diet (n = 6 - 17). (H) Average body weight of 
female control () and IRΔAgRP () mice on high fat diet (n = 9 - 20). Displayed values are means ± S.E.M.. 
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Furthermore, male and female IR∆POMC and IR∆AgRP mice showed unaltered relative 
(corrected for body weight) fat pad weights both on normal and high fat diet as compared to 
controls (Figure 20). 
 
Figure 20: Epigonadal fat pad weights of female and male IRΔPOMC and IRΔAgRP mice. 
(A) Relative parametrial fat pad weights of female control and IRΔPOMC mice on normal diet (ND) and high fat 
diet (HFD) (n = 10 - 16) at the age of 20 weeks. (B) Relative parametrial fat pad weights of female control and 
IRΔAgRP mice on normal diet (ND) and high fat diet (HFD) (n = 10 - 14) at the age of 15 weeks. (C) Relative 
epididymal fat pad weights of male control and IRΔPOMC mice on normal diet (ND) and high fat diet (HFD) (n = 
11 - 18) at the age of 20 weeks. (D) Relative epididymal fat pad weights of male control and IRΔAgRP mice on 
normal diet (ND) and high fat diet (HFD) (n = 8 - 15) at the age of 15 weeks. Displayed values are means ± 
S.E.M.. 
 
 
Taken together, these data indicate that energy homeostasis in mice is unaffected by 
selective, targeted disruption of the insulin receptor gene in POMC or AgRP neurons of the 
ARC. 
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Next, the expression of different neuropeptides critically involved in the regulation of 
energy homeostasis was determined. Expression of anorexigenic neuropeptides (e.g. POMC) 
and orexigenic neuropeptides (such as NPY and AgRP) did not differ between IR∆POMC and 
control mice (Figure 21 A). IR∆AgRP mice did exhibit a slight increase in AgRP expression 
(Figure 21 B), which is expected since insulin suppresses NPY and AgRP expression (186, 
266, 267). 
 
 
 
Figure 21: Hypothalamic neuropeptide expression in IRΔPOMC and IRΔAgRP male mice. 
(A) Neuropeptide expression in male control (n = 8) and IRΔPOMC (n = 12) mice at the age of 12 weeks. (B) 
Neuropeptide expression in male control (n = 8) and IRΔAgRP (n = 8) mice at the age of 12 weeks. Displayed 
values are means ± S.E.M.. 
 
 
 
Since mice with mutations in the melanocortin system develop an increased body 
length (268), body length was measured in control and insulin receptor knockout mice (Figure 
22). This analysis revealed no alterations in body length in these animals, a further indication 
of the intact function of the melanocortin pathway despite the absence of insulin receptor 
signaling in either POMC or AgRP neurons. 
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Figure 22: Body length of IRΔPOMC and IRΔAgRP male mice. 
(A) Naso-anal body length of male control (n = 10) and IRΔPOMC (n = 9) mice at the age of 15 weeks. (B) Naso-
anal body length of female control (n = 10) and IRΔAgRP (n = 11) mice at the age of 15 weeks. Displayed values 
are means ± S.E.M.. 
 
 
3.4 IR∆AgRP mice fail to fully suppress hepatic glucose production 
Since global knockout of the insulin receptor in brain and pharmacological studies 
using infusion of insulin or a small-molecule insulin mimetic had shown effects on glucose 
homeostasis and hepatic glucose production (47, 58), these parameters were assessed in 
control, IR∆POMC and IR∆AgRP mice. Fasted blood glucose and serum insulin concentrations 
were comparable between male IR∆POMC and IR∆AgRP mice as compared to controls (Figure 
23). Moreover, glucose tolerance tests revealed no major disturbance of glucose homeostasis 
in either of the knockout mice both on normal diet or high fat diet (Figure 24).  
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Figure 23: Fasting blood glucose levels and serum insulin concentrations in IRΔPOMC and IRΔAgRP male 
mice. 
(A) Average fasting blood glucose levels of control (n = 18) and IRΔPOMC (n = 14) mice at the age of 10 weeks. 
(B) Average fasting blood glucose levels of control (n = 10) and IRΔAgRP (n = 14) mice at the age of 10 weeks. 
(C) Serum insulin concentrations of control (n = 10 - 12) and IRΔPOMC (n = 12 - 20) mice on normal (ND) and 
high fat diet (HFD) at the age of 15 weeks. (D) Serum insulin concentrations of control (n = 11 - 15) and IRΔAgRP 
(n = 8 - 15) mice on normal (ND) and high fat diet (HFD) at the age of 15 weeks. Displayed values are means ± 
S.E.M.. 
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Figure 24: Glucose tolerance in IRΔPOMC and IRΔAgRP male mice. 
(A) Glucose tolerance test of control (n = 13) and IRΔPOMC (n = 11) mice on normal diet (ND) at the age of 10 
weeks. (B) Glucose tolerance test of control (n = 7) and IRΔPOMC (n = 17) mice on high fat diet (HFD) at the age 
of 10 weeks. (C) Glucose tolerance test of control (n = 10) and IRΔAgRP (n = 14) mice on normal diet (ND) at the 
age of 10 weeks. (D) Glucose tolerance test of control (n = 9) and IRΔAgRP (n = 14) mice on high fat diet (HFD) 
at the age of 10 weeks. Displayed values are means ± S.E.M.. 
 
Since the contribution of individual tissues is impossible to assess by standard glucose 
and insulin measurements, euglycemic-hyperinsulinemic clamps, which allow measurement 
of insulin sensitivity in vivo without causing hypoglycemia, were performed on the three 
different groups of mice at 15 weeks of age. After an overnight fasting period, mice received 
a constant infusion of insulin to produce hyperinsulinemia, and a variable infusion of glucose 
to maintain euglycemia over a steady state period of 30 minutes (Figure 25). Co-
administration of D-[3-3H]- and 2-Deoxy-D-[1-14C] glucose enables the rate of glucose 
production under basal and hyperinsulinemic steady state conditions to be measured, as well 
as determination of the rate of insulin-stimulated tissue-specific glucose uptake.  
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Figure 25: General scheme of a euglycemic-hyperinsulinemic clamp. 
After starvation for 16 hours, mice received a continuous intravenous infusion of a D-[3-3H]-Glucose tracer 
solution. At the end of the basal period (50 min) a blood sample (basal) was collected for determination of basal 
parameters and insulin infusion was started. Blood glucose levels were determined every 10 minutes and 
physiological blood glucose levels (between 100 and 140 mg/dl) were maintained by adjusting a 20% glucose 
infusion to prevent a counterregulatory response to hypoglycemia. Approximately 120 minutes before steady 
state was achieved, a bolus of 2-Deoxy-D-[1-14C]-Glucose was infused. Steady state was ascertained when 
glucose measurements were constant for at least 30 min at a fixed glucose infusion rate. During the steady state, 
blood samples were collected for the measurement of steady state parameters.  
 
The glucose infusion rate required to maintain euglycemia during steady state 
conditions, which indicates the balance between the rates of glucose production and glucose 
utilization when insulin levels are high, was comparable between the different groups (Figure 
26 A, B). Hepatic glucose production was also not significantly different between the three 
groups of mice under basal conditions. However, whereas control and IR∆POMC mice 
significantly suppressed hepatic glucose production during steady state conditions (Figure 26 
C, D), insulin did not significantly reduce hepatic glucose production in IR∆AgRP mice (Figure 
26 C, D). Thus, insulin action on AgRP neurons is required for the ability of peripherally 
applied insulin to efficiently suppress hepatic glucose production.  
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Figure 26: Regulation of glucose homeostasis in IRΔPOMC and IRΔAgRP mice. 
(A) Blood glucose levels during the clamp period in control (, n = 13), IRΔPOMC (, n = 9) and IRΔAgRP (, n = 
11) mice at the age of 15 weeks. (B) Glucose infusion rates during the clamp period in control (, n = 13), 
IRΔPOMC (, n = 9) and IRΔAgRP (, n = 11) mice at the age of 15 weeks. (C) Hepatic glucose production (HGP) 
measured under basal and steady state conditions during the clamp in control (n = 13), IRΔPOMC (n = 9) and 
IRΔAgRP (n = 11) mice. (D) Percentage suppression of hepatic glucose production (HGP) by insulin as measured 
under steady state conditions during the clamp in control (n = 13), IRΔPOMC (n = 9) and IRΔAgRP (n = 11) mice. 
Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01. 
 
 
Determination of tissue-specific glucose uptake rates showed similar rates of insulin-
stimulated glucose uptake in brain and skeletal muscle in the different groups of mice (Figure 
27). However, insulin-stimulated glucose uptake in white adipose tissue of IR∆AgRP mice (but 
not IR∆POMC mice) was significantly increased compared to control mice (Figure 27), 
indicating some form of compensatory response on increased hepatic glucose production or 
tissue cross talk. 
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Figure 27: Insulin-stimulated tissue glucose uptake in euglycemic-hyperinsulinemic clamps. 
Tissue-specific insulin-stimulated glucose uptake rates in brain, white adipose tissue (WAT) and skeletal muscle 
(Skel.musc.) from male control (n = 13), IRΔPOMC (n = 9) and IRΔAgRP (n = 11) mice. Displayed values are means 
± S.E.M.; *, p ≤ 0.05. 
 
 
3.5 Reduced hepatic IL-6 expression in IR∆AgRP mice 
It has recently been shown that insulin, acting through the CNS, induces hepatic 
Interleukin-6 (IL-6) expression and activates STAT3 in liver parenchymal cells, thereby 
suppressing hepatic gluconeogenesis (48). Therefore, to further investigate the molecular 
mechanism underlying the failure of IR∆AgRP mice to efficiently suppress hepatic glucose 
production, IL-6 mRNA expression was determined in the liver of the different groups of 
mice under basal and clamp steady state conditions. This revealed a 30% reduction of steady 
state hepatic IL-6 expression in IR∆AgRP mice (Figure 28 A), whereas basal IL-6 expression 
levels were unaltered between the different groups (Figure 28 B). 
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Figure 28: Hepatic interleukin-6 expression under steady state and basal conditions in euglycemic-
hyperinsulinemic clamps. 
(A) IL-6 mRNA expression in liver at the end of the euglycemic-hyperinsulinemic clamp of male control (n = 
13), IRΔPOMC (n = 9) and IRΔAgRP (n = 11) mice. (B) IL-6 mRNA expression in liver under basal conditions of 
control (n = 6), IRΔPOMC (n = 5) and IRΔAgRP (n = 4) mice. Displayed values are means ± S.E.M.; **, p ≤ 0.01. 
 
 
Moreover, Western blot analysis of clamp steady state expression of the glucose-6-
phosphatase protein (G6Pase), a key enzyme of gluconeogenesis, revealed a significantly 
upregulated expression in liver of IR∆AgRP mice compared to control and IR∆POMC mice (Figure 
29 A). On the other hand, basal expression of G6Pase was unaltered in liver of IR∆AgRP mice 
as compared to control and IR∆POMC mice (Figure 29 B).  
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Figure 29: Hepatic G6Pase-expression under steady state and basal conditions in euglycemic-
hyperinsulinemic clamps. 
(A) Western blot analysis (upper panel) of the glucose-6-phosphatase (G6Pase) α subunit and β-Actin (loading 
control) in liver at the end of euglycemic-hyperinsulinemic clamps of control (n = 4), IRΔPOMC (n = 5) and 
IRΔAgRP (n = 4) mice. Densitometrical analysis (lower panel) of glucose-6-phosphatase (G6Pase) α subunit 
expression in IRΔPOMC and IRΔAgRP mice as compared to controls. (B) Western blot analysis (upper panel) of the 
glucose-6-phosphatase (G6Pase) α subunit and β-Actin (loading control) in liver under basal conditions of 
control (n = 4), IRΔPOMC (n = 5) and IRΔAgRP (n = 4) mice. Densitometrical analysis (lower panel) of basal 
glucose-6-phosphatase (G6Pase) α subunit expression in IRΔPOMC and IRΔAgRP mice as compared to controls. 
Displayed values are means ± S.E.M.; **, p ≤ 0.01; ***, p ≤ 0.001. 
 
 
Additionally, to investigate if other hepatic cytokines and chemokines are involved in 
the failure of IR∆AgRP mice to efficiently suppress hepatic glucose production, mRNA 
expression levels of various cytokines and chemokines involved in inflammation were 
analyzed in liver of the different groups of mice under clamp steady state conditions. This 
revealed no significant differences between control, IR∆POMC and IR∆AgRP mice (Figure 30), 
further indicating that the failure of IR∆AgRP mice to efficiently suppress hepatic glucose 
production is based on impaired insulin-stimulated hepatic IL-6 expression. 
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Figure 30: Hepatic cytokine and chemokine expression at the end of euglycemic-hyperinsulinemic clamps. 
mRNA expression of cytokines and chemokines in liver at the end of euglycemic-hyperinsulinemic clamps of 
control (n = 13), IRΔPOMC (n = 9) and IRΔAgRP (n = 11) mice. TNF-α: tumor necrosis factor alpha , Ccl2: 
chemokine (C-C motif) ligand 2 (Mcp-1), Ccl3: chemokine (C-C motif) ligand 3 (Mip1-alpha), Ccl5: chemokine 
(C-C motif) ligand 5 (RANTES), Cxcl2: chemokine (C-X-C motif) ligand 2 (Mip2-alpha). Displayed values are 
means ± S.E.M.. 
 
 
Taken together, these data indicate that IR∆AgRP mice fail to efficiently suppress 
hepatic glucose production in a euglycemic-hyperinsulinemic clamp, and that this is 
paralleled by impaired insulin-stimulated hepatic IL-6 expression and a failure to suppress 
expression of the glucose-6-phosphatase protein.  
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3.6 Inactivation of the insulin receptor gene in dopaminergic cells 
Tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, is a well-
established marker of dopaminergic neurons. To investigate the role of insulin signaling in 
tyrosine hydroxylase (Th)-expressing cells, the insulin receptor gene was inactivated 
specifically in these cells. To this end, knock-in mice expressing Cre recombinase from the 
3´-untranslated region of the endogenous tyrosine hydroxylase gene by means of an internal 
ribosomal entry sequence (IRES) (261) were crossed with mice carrying a loxP-flanked 
insulin receptor gene (IRlox/lox) (Figure 31) (58).  
 
 
Figure 31: Restricted inactivation of the insulin receptor gene in tyrosine hydroxylase-expressing cells. 
Map of a part of the endogenous tyrosine hydroxylase (Th) locus (exon 11-13) and the knock-in cassette. Black 
boxes represent translated exons of the Th gene and the open box stands for the 3’ untranslated region. The stop 
codon is depicted by an asterisk (*). The knock-in cassette is located between the stop codon and poly A signal 
in Th exon 13.  
 
In IRlox/lox mice, positive for expression of Cre recombinase from the 3’-untranslated 
region of the tyrosine hydroxylase gene, the loxP-flanked insulin receptor gene is removed 
upon Cre-mediated recombination, leading to the inactivation of the insulin receptor 
selectively in Th-expressing cells (Figure 32). 
 
 
 
Figure 32: General scheme of mice with restricted inactivation of the insulin receptor gene in tyrosine 
hydroxylase-expressing cells (IRΔTh). 
Mice, homozygous for a loxP-flanked exon 4 of the insulin receptor allele (IRlox/lox) were crossed with mice 
expressing the Cre protein from the 3’-untranslated region of the tyrosine hydroxylase gene. Only one loxP-
flanked allele is depicted here.  
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To analyze cell type-specific inactivation of the insulin receptor, Cre-mediated 
recombination was visualized by crossing ThIRESCre mice to the Z/EG reporter mouse strain 
which carries a transgene comprising a loxP-flanked βgeo fusion gene followed by the coding 
sequence of a GFP protein (254). In this configuration, GFP is only expressed in cells 
expressing the Cre recombinase. These mice showed a pattern of GFP immunoreactivity in 
the ventral tegmental area (VTA) and the substantia nigra (SN) reflecting the described 
expression pattern of endogenously expressed tyrosine hydroxylase (Figure 33), consistent 
with the previously demonstrated colocalization of endogenous tyrosine hydroxylase 
expression and Cre recombinase activity (261). 
 
 
Figure 33: Verification of Cre-mediated recombination in ThIRESCre mice. 
ThIRESCre mice were mated with Z/EG reporter mice and immunohistochemistry for enhanced GFP was 
performed on brain sections of double heterozygous reporter mice (Z/EG+/- ThIRESCre). Cre mediated 
recombination removes the loxP-flanked neomycin resistance gene, thus GFP is transcribed only in tyrosine 
hydroxylase-expressing cells. Cre recombinase activity is present in the ventral tegmental area and the substantia 
nigra. GFP-positive cells, brown. Scale bar: 100 µm. 
 
 
In the VTA, insulin has been shown to activate the intracellular PI3 kinase cascade, 
which results in the generation of PIP3 (249). Therefore, functional effects of restricted 
insulin receptor deficiency in Th-expressing cells on insulin’s ability to activate the PI3 
kinase pathway were determined. ThIRESCre as well as IRΔTh mice were crossed to the LacZ 
reporter mouse strain in which transcription of the β-galactosidase gene (LacZ) under control 
of the ubiquitously expressed Rosa26 promoter is prevented by a floxed hygromycin 
resistance gene, thus leading to a β-galactosidase expression only in cells expressing the Cre 
recombinase (253). 
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In the basal state, little immunoreactive PIP3 was detectable in Th-expressing neurons 
of control and IRΔTh reporter mice. In control mice, insulin treatment resulted in activation of 
PIP3 formation in Th-expressing and non-Th-expressing neurons of the VTA/SN (Figure 34 
A, B). In contrast, in IRΔTh mice insulin stimulation resulted in PIP3 formation in non-Th-
expressing cells, but it failed to activate PIP3 formation in Th-expressing neurons (Figure 34 
A, C). These data indicate efficient and specific insulin receptor inactivation in Th-expressing 
cells of IR∆Th mice.  
 
Figure 34: PIP3 formation in neurons of control and IR∆Th reporter mice. 
(A) Double immunohistochemistry of ARC neurons of control and IRΔTh reporter mice was performed in 
overnight fasted mice, which were intravenously injected with either saline or insulin and sacrificed 10 min 
afterwards. Arrows indicate 1 Th-expressing neuron and 1 non-Th-expressing neuron in each panel. (B) 
Quantification of PIP3 levels in control reporter mice in the basal state (-) and after insulin (+) stimulation. 
Values are means ± S.E.M. of sections obtained from 2 unstimulated and 3 insulin-stimulated control mice. *, p 
≤ 0.05. (C) Quantification of PIP3 levels in IRΔTh reporter mice in the basal state (-) and after insulin (+) 
stimulation. Values are means ± S.E.M. of sections obtained from 2 unstimulated and 4 insulin-stimulated IRΔTh 
mice. Blue (DAPI), DNA; red, β-gal (Th-expressing neurons); green, PIP3. 
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To rule out that fertility is altered in mice with inactivation of the insulin receptor in 
Th-expressing cells, parameters of fertility were assessed in IRΔTh mice. This revealed no 
significant differences concerning litter-to-litter intervals, litter size and morphology of 
reproductive organs between control (IRlox/lox) and IRΔTh mice, indicating that insulin 
signaling in these cells is not required for control of fertility (Figure 35). 
 
 
Figure 35: Fertility of IRΔTh mice. 
(A) Mean litter intervals for control and IRΔTh mice assessed over a period of at least three litters (n = 3 
breedings). (B) Mean litter size for control and IRΔTh mice assessed over a period of at least three litters (n = 3 
breedings). (C) Representative hematoxylin/eosin staining of ovaries and testes from control and IRΔTh mice. 
Scale bar 100µm. Displayed values are means ± S.E.M.. 
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3.7 Increased adiposity in IRΔTh mice 
To investigate the impact of insulin receptor inactivation in Th-expressing cells on the 
regulation of energy homeostasis, body weight of female and male control and IR∆Th mice 
was monitored from weaning until 20 weeks of age under normal diet conditions. Both, 
female and male IR∆Th mice exhibited an increased body weight from approximately 7 weeks 
of age on as compared to control mice (Figure 36 A, B). To investigate whether increased 
body weight in IR∆Th mice results from an increase in body fat mass, the amount of 
epigonadal fat was examined in female and male control and IR∆Th mice under normal diet 
conditions. Consistent with the body weight curves, female and male IR∆Th mice displayed 
significantly increased epigonadal fat pad mass at the age of 20 weeks compared to controls 
(Figure 36 C, D). Consistent with this, brown adipose tissue mass was also increased in 
female and male IR∆Th mice at the age of 20 weeks (Figure 36 E, F). 
 
To further confirm increased adiposity in IR∆Th mice, body fat content of 20-week-old 
mice was determined by in vivo magnetic resonance spectrometry. Mean body fat content was 
increased in female and male IR∆Th mice as compared to controls (Figure 36 G, H). Consistent 
with these findings, adiposity was accompanied by increased concentrations of circulating 
leptin (Figure 36 I, J). 
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Figure 36: Body weight, fat content and leptin levels of IRΔTh mice. 
(A) Average body weight of female control () and IRΔTh () mice under normal diet conditions (n = 27 - 30). 
(B) Average body weight of male control () and IRΔTh () mice under normal diet conditions (n = 13 - 22). 
(C) Parametrial fat pad weight of female control and IRΔTh mice (n = 29) at the age of 20 weeks. (D) Epididymal 
fat pad weight of male control and IRΔTh mice (n = 15 - 17) at the age of 20 weeks. (E) Brown adipose tissue 
(BAT) weight of female control and IRΔTh mice (n = 29) at the age of 20 weeks. (F) Brown adipose tissue (BAT) 
weight of male control and IRΔTh mice (n = 15 - 17) at the age of 20 weeks. (G) Average body fat content of 
female control and IRΔTh mice (n = 29) at the age of 20 weeks measured by nuclear magnetic resonance. (H) 
Average body fat content of male control and IRΔTh mice (n = 15 - 17) at the age of 20 weeks measured by 
nuclear magnetic resonance. (I) Serum leptin concentrations of female control and IRΔTh mice (n = 17 - 20) under 
normal diet conditions at the age of 20 weeks. (J) Serum leptin concentrations of male control and IRΔTh mice (n 
= 7 - 9) under normal diet conditions at the age of 20 weeks. Displayed values are means ± S.E.M.; *, p ≤ 0.05; 
**, p ≤ 0.01; ***, p ≤ 0.001. 
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Taken together, these results indicate that inactivation of the insulin receptor gene in 
Th-expressing cells results in increased body weight and adiposity. 
 
3.8 Unaltered glucose homeostasis in IRΔTh mice 
Next, glucose metabolism was compared in control and IR∆Th mice. Glucose and 
insulin tolerance tests revealed no alterations in glucose tolerance and insulin sensitivity in 
female and male IR∆Th mice compared to control mice (Figure 37). Thus, inactivation of the 
insulin receptor in Th-expressing cells has no effect on glucose homeostasis in these mice. 
Consistent with theses findings, serum insulin concentrations of female and male IR∆Th mice 
were similar as compared to controls at an age of 9 weeks (Figure 38 A, B). However, serum 
insulin concentrations of female and male IR∆Th mice were significantly increased at an age of 
20 weeks (Figure 38 C, D).  
 
Figure 37: Glucose tolerance and insulin sensitivity in IR∆Th mice. 
(A, B) Glucose tolerance tests of overnight fasted female (left panel, n = 15 - 20) and male (right panel, n = 9 - 
13) control and IR∆Th mice under normal diet conditions at the age of 10 weeks. (C, D) Insulin tolerance tests of 
female (left panel, n = 15 - 20) and male (right panel, n = 9 - 13) control and IR∆Th mice under normal diet 
conditions at the age of 11 weeks. Displayed values are means ± S.E.M.. 
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Figure 38: Serum insulin concentrations in IR∆Th mice. 
(A) Serum insulin concentrations of female control (n = 27) and IR∆Th (n = 26) mice under normal diet 
conditions at the age of 9 weeks. (B) Serum insulin concentrations of male control (n = 14) and IR∆Th (n = 12) 
mice under normal diet conditions at the age of 9 weeks. (C) Serum insulin concentrations of female control (n = 
20) and IR∆Th (n = 16) mice under normal diet conditions at the age of 20 weeks. (D) Serum insulin 
concentrations of male control (n = 8) and IR∆Th (n = 7) mice under normal diet conditions at the age of 20 
weeks. Displayed values are means ± S.E.M.. 
 
3.9 Unaltered energy expenditure but increased food intake in IRΔTh mice 
To further analyze the mechanism underlying the increased body weight and adiposity 
of IR∆Th mice, energy intake and energy expenditure were assessed in these mice. Female and 
male IR∆Th mice displayed an increased food intake, both at 6 and 13 weeks of age as 
compared to control littermates (Figure 39). 
 
Figure 39: Food intake of IR∆Th mice. 
(A) Daily food intake of female control and IR∆Th mice under normal diet conditions at the age of 6 weeks (n = 
11 - 12). (B) Daily food intake of female control and IR∆Th mice under normal diet conditions at the age of 13 
weeks (n = 12 - 13). (C) Daily food intake of male control and IR∆Th mice under normal diet conditions at the 
age of 6 weeks (n = 10 - 13). (D) Daily food intake of male control and IR∆Th mice under normal diet conditions 
at the age of 13 weeks (n = 11). Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01. 
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To investigate whether the increased adiposity in IR∆Th mice may also result from a 
decreased energy expenditure and/or locomotor activity, energy expenditure and basal 
locomotor activity of IR∆Th mice were analyzed at 20 weeks of age. This analysis revealed 
unaltered oxygen consumption, assessed by indirect calorimetry, in female and male IR∆Th 
mice as compared to control mice during both day and night phase (Figure 40 A, C). Basal 
locomotor activity in both female and male IR∆Th mice was also indistinguishable to control 
animals during both day and night phase (Figure 40 B, D). 
 
 
Figure 40: Basal metabolic rate and locomotor activity in IR∆Th mice. 
(A) Mean oxygen consumption (VO2) of female control (n = 11) and IR∆Th (n = 7) mice under normal diet 
conditions measured by indirect calorimetry at the age of 20 weeks. (B) Basal locomotor activity of female 
control (n = 11) and IR∆Th (n = 7) mice under normal diet conditions at the age of 20 weeks. (C) Mean oxygen 
consumption (VO2) of male control (n = 7) and IR∆Th (n = 6) mice under normal diet conditions measured by 
indirect calorimetry at the age of 20 weeks. (D) Basal locomotor activity of male control (n = 7) and IR∆Th (n = 
6) mice under normal diet conditions at the age of 20 weeks. Displayed values are means ± S.E.M.. 
 
Taken together, these data indicate that increased body weight and adiposity in IR∆Th 
mice is the consequence of an increased food intake but not alterations in energy expenditure 
and/or locomotor activity. 
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3.10 Increased expression of tyrosine hydroxylase and dopamine receptor 2 
in the ventral tegmental area of IR∆Th mice 
Next, expression levels of different genes critically involved in dopamine signaling in 
brain regions related to the mesolimbic and nigrostriatal dopamine system were determined in 
the VTA, the nucleus accumbens (NAc), and the caudate putamen (CPu) of female control 
and IR∆Th mice at the age of 20 weeks. This revealed significantly increased mRNA levels of 
Th and dopamine receptor 2 (D2R) in the VTA of IR∆Th mice as compared to controls (Figure 
41 A).  
 
 
Figure 41: Expression levels of genes critically involved in dopamine signaling in the VTA, NAc, and CPu 
of IR∆Th mice. 
(A) Expression of MAOB, COMT, TH, AAAD, DAT, and D2R in the ventral tegmental area (VTA) of female 
control (n = 11) and IR∆Th (n = 11) mice. (B) Expression of MAOB, COMT, D1R, D2R, and D3R in the nucleus 
accumbens (NAc) of female control (n = 11) and IR∆Th (n = 11) mice. (C) Expression of MAOB, COMT, D1R, 
D2R, and D3R in the caudate putamen (CPu) of female control (n = 11) and IR∆Th (n = 11) mice. AAAD: 
aromatic L-amino acid decarboxylase, COMT: catechol-O-methyl transferase, D1R: dopamine receptor 1, D2R: 
dopamine receptor 2, D3R: dopamine receptor 3, DAT: dopamine transporter, MAOB: monoamine oxidase B, 
Th: tyrosine hydroxylase. Displayed values are means ± S.E.M.; *, p ≤ 0.05; **, p ≤ 0.01. 
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On the other hand, expression levels of monoamine oxidase B (MAOB), catechol-O-
methyl transferase (COMT), aromatic L-amino acid decarboxylase (AAAD) and the 
dopamine transporter (DAT) were unaltered in the VTA of female IR∆Th mice as compared to 
controls (Figure 41 A). Moreover, expression levels of MAOB, COMT, dopamine receptor 1 
(D1R), D2R, and dopamine receptor 3 (D3R) were unaltered in the NAc and CPu of these 
mice (Figure 41 B, C). 
 
Thus, inactivation of the insulin receptor gene in Th-expressing cells leads to 
increased mRNA expression levels of tyrosine hydroxylase and dopamine receptor 2 in the 
VTA. 
 
3.11 Insulin action decreases excitatory inputs on dopaminergic neurons in 
the VTA 
To analyze insulin action on the dopaminergic system in vivo, long-term euglycemic-
hyperinsulinemic clamp studies were performed in C57BL/6 male mice at 11 weeks of age. 
Fasted animals received continuous intravenous infusion of either somatostatin and glucose 
alone (control group), or insulin, somatostatin and glucose (treatment group) over a period of 
six hours (Figure 42 A).  
 
Both groups received glucose infusion adapted to their blood glucose level, and thus 
remained in the euglycemic range of 100 to 140 mg/dl (Figure 42 B). As expected, serum 
insulin levels of the insulin-treated group increased steadily over the treatment period, 
whereas serum insulin levels remained below basal in the control group (Figure 42 C). 
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Figure 42: Long-term euglycemic-hyperinsulinemic clamps in C57BL/6 mice. 
(A) Experimental design for euglycemic-hyperinsulinemic clamp studies in C57BL/6 mice. Fasted animals 
received continuous intravenous infusion of either somatostatin and glucose alone (control group), or, insulin, 
somatostatin and glucose (treatment group) over a period of six hours. At the beginning a blood sample (0h) was 
collected for determination of basal insulin levels and insulin infusion was started subsequently with a bolus 
infusion. Blood glucose levels were determined every 20-30 minutes and physiological blood glucose levels 
(between 100 and 140 mg/dl) were maintained by adjusting a 20% glucose infusion. During and at the end of the 
clamp additional blood samples were collected for determination of insulin levels (3h, 6h). (B) Blood glucose 
levels in control (open symbols) and treatment (filled symbols) group during a euglycemic-hyperinsulinemic 
clamp (n = 13 per group). (C) Serum insulin levels in control (open bars) and treatment (filled bars) group before 
(0h) and during (3h, 6h) a euglycemic-hyperinsulinemic clamp (n = 13 per group). Displayed values are means ± 
S.E.M.; ***, p ≤ 0.001. 
 
 
After 6 hours, the mice were sacrificed and the number and type of synapses on 
dopaminergic neurons in the VTA were determined by electron microscopy in brains of 
animals from both groups. This revealed a significant decrease in the number of total 
synapses on dopaminergic neurons in insulin-treated animals compared to untreated animals, 
which could be accounted for entirely by a significant decrease in asymmetrical (excitatory) 
synapses (Figure 43). In contrast, inhibitory inputs (symmetrical synapses) were comparable 
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between insulin-treated and untreated animals (Figure 43). Thus, prolonged insulin action in 
vivo leads to a decrease of excitatory synapses on dopaminergic cells. 
 
 
 
Figure 43: Synaptic input on dopaminergic neurons in C57BL/6 mice after long-term euglycemic-
hyperinsulinemic clamp studies. 
Quantification of total, stimulatory (asymmetrical) and inhibitory (symmetrical) synapses on dopaminergic 
neurons in the ventral tegmental area of wild type mice from the control (open bars) and the treatment (filled 
bars) group (n = 5 per group) after long-term euglycemic-hyperinsulinemic clamp studies. Displayed values are 
means ± S.E.M.; *, p ≤ 0.05. 
 
 
Taken together, these data demonstrate that prolonged insulin action in vivo results in 
a decrease of excitatory inputs on dopaminergic neurons in the VTA of wildtype mice. 
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4 Discussion 
4.1 Role of central insulin signaling in regulation of energy homeostasis 
and glucose metabolism 
Obesity and insulin-resistant type 2 diabetes mellitus are intimately connected diseases 
and their incidences are steadily increasing worldwide (2). Therefore, a detailed 
understanding of how energy homeostasis is regulated, which signaling pathways are 
involved and how their activity is influenced is a prerequisite for the development of new 
therapeutical strategies to treat the obesity as well as the diabetes epidemic. 
Already in the 1940s and 1950s, classic lesion experiments in the rodent hypothalamus 
could identify the brain as a critical organ in the regulation of body weight and energy 
homeostasis. In 1953, Kennedy first proposed that hormonal signals are released into the 
blood stream in proportion to the body’s energy stores and are able to regulate body weight by 
influencing energy intake and expenditure (141). Moreover, parabiosis studies provided direct 
evidence that an intact hypothalamus is required for the regulating action of hormonal satiety 
signals produced in obesity and created the link between circulating satiety signals and their 
hypothalamic target regions (142).  
The finding that insulin, when infused into the brain, decreases food intake and body 
weight led to the proposal by Woods and Porte that insulin serves as an adiposity signal in the 
brain, where it provides a signal related to the amount of body fat and causes a long-term, net 
catabolic response, decreasing food intake and increasing energy expenditure (50-53). 
Generation of mice in which the insulin receptor was genetically deleted in all CNS neurons 
and glial cells by Cre-loxP-mediated recombination (NIRKO mice) display diet-sensitive 
obesity, insulin resistance and impaired fertility, and thus ultimately highlight the role of 
central insulin action in regulation of fuel metabolism and reproduction (58). Insulin, 
circulating in the periphery, has access to the brain via a saturable transporter across the 
blood-brain barrier and insulin receptors are widely expressed in the brain, with the highest 
concentrations in the olfactory bulb, hypothalamus, cerebral cortex, cerebellum and the 
hippocampus (54-57, 269). 
Besides the brain’s ability to integrate peripheral hormonal signals in order to regulate 
energy intake and energy expenditure, it has long been suggested that the CNS plays an 
essential role in the control of peripheral blood glucose levels. In 1855, the French 
physiologist Claude Bernard demonstrated that the liver serves as a reservoir for glucose 
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(143). He also postulated that the CNS regulates peripheral glucose metabolism based on the 
observation that lesioning the floor of the fourth ventricle in rabbits results in glucosuria 
(143). In 2002, Obici et al. defined the hypothalamus as one important extrahepatic site of 
insulin action to regulate hepatic glucose production (47). This finding has led to the concept 
that besides regulating body weight, food intake and reproductive endocrinology, 
hypothalamic insulin signaling also controls glucose metabolism in the periphery. Along this 
line, insulin fails to efficiently suppress hepatic glucose production during euglycemic-
hyperinsulinemic clamps in NIRKO mice (48), demonstrating that functional insulin receptor 
signaling in the CNS is a prerequisite for peripherally applied insulin to suppress hepatic 
glucose production. Additionally, recent studies demonstrated that hypothalamic insulin 
signaling is required for blood glucose lowering during insulin treatment of diabetes mellitus 
in rats (49). 
 
Several studies indicate that the hypothalamic melanocortin system is an important 
target of the actions of insulin to regulate food intake and body weight (193, 194, 266, 270). 
Hypothalamic neurons that express the orexigenic neuropeptides NPY and AgRP, as well as 
those expressing the anorexigenic neuropeptide POMC co-express insulin receptors, and 
administration of insulin into the third cerebral ventricle of fasted rats increased expression of 
POMC mRNA and decreased expression of NPY mRNA (193, 266). Moreover, 
pharmacological studies demonstrating that MC4 receptor antagonists prevent the reduction in 
food intake caused by third-ventricular insulin administration suggest that the hypothalamic 
melanocortin system mediates the anorexigenic effects of central insulin (193).  
 
Taken together, recent experiments have defined insulin action in the CNS as a critical 
determinant of energy homeostasis and of peripheral glucose metabolism in rodents. 
 
4.2 Inactivation of the insulin receptor gene specifically in POMC and 
AgRP neurons 
Our understanding about the role of insulin action in the CNS to regulate energy 
homeostasis and glucose metabolism has significantly improved over the last years. 
Nevertheless, the identity of the insulin-responsive neurons that mediate these effects 
remained elusive. Therefore, to precisely define the neuronal populations mediating insulin’s 
central effects on energy and glucose homeostasis, the insulin receptor gene was specifically 
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inactivated in POMC- and AgRP-expressing neurons of mice by Cre-loxP-mediated 
recombination (IRΔPOMC and IRΔAgRP mice). These mice display unaltered insulin receptor 
expression in the hypothalamus, in the rest of the brain as well as in peripheral tissues and 
normal insulin signaling in skeletal muscle and liver, which is consistent with restricted 
inactivation of the insulin receptor in defined neuronal populations of the hypothalamus. 
Furthermore, insulin’s ability to activate the PI3 kinase pathway was blunted specifically in 
POMC and AgRP neurons of IRΔPOMC and IRΔAgRP mice, respectively. Taken together, mice 
with specific inactivation of the insulin receptor in either POMC or AgRP neurons provide an 
adequate tool to study the role of insulin signaling in these cells in vivo.  
 
Previous studies have demonstrated that AgRP neurons play a critical role in the 
maintenance of energy and glucose homeostasis (173, 174). Although acute ablation of AgRP 
neurons in adult mice results in hypoglycemia in these experiments, it is not possible to 
determine the role of AgRP neurons in glucose homeostasis, since these animals also exhibit 
severe cachexia from complete suppression of food intake. In contrast, POMC or AgRP 
neuron-restricted inactivation of the insulin receptor does not interfere with the regulation of 
food intake or energy homeostasis under normal conditions, thus allowing determination of 
direct effects on other tissues in a physiological setting. 
 
4.2.1 Role of insulin action on POMC and AgRP neurons in the regulation of energy 
homeostasis 
Strikingly, neither POMC- nor AgRP-restricted insulin receptor knockout mice exhibit 
alterations in energy homeostasis, indicating that insulin receptor signaling in neurons other 
than, or additional to, POMC or AgRP cells is required for insulin’s ability to control energy 
homeostasis. Earlier studies have put particular emphasis on the regulation of POMC-, NPY- 
and AgRP-expression by insulin in insulin’s ability to regulate food intake (19, 193, 266). 
Acute central administration of insulin in fasted animals has been shown to result in increased 
POMC and decreased NPY expression, without affecting AgRP expression (187, 193, 194) 
and a very recent study demonstrated that insulin directly regulates NPY and AgRP 
expression through a MAPK-dependent pathway in a hypothalamic cell line (271). Moreover, 
regulation of FOXO1 activity through the PI3 kinase/Akt signaling pathway has been 
demonstrated to promote POMC expression while inhibiting AgRP expression (192, 267). 
However, expression of the anorexigenic neuropeptide POMC as well as expression of 
the orexigenic neuropeptides NPY/AgRP is unaltered in IR∆POMC mice. While POMC and 
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NPY expression are comparable to controls in IR∆AgRP mice, these mice show a slight increase 
in AgRP mRNA expression. Since AgRP neurons are essential for the maintenance of energy 
homeostasis (173, 174), these experiments reveal that lack of insulin-stimulated AgRP- and/or 
NPY-regulation can be physiologically compensated for when signaling by other hormonal or 
nutritional mediators is intact.  
Furthermore, the finding that IR∆POMC and IR∆AgRP mice show a food intake similar to 
control mice contrasts with the hyperphagia found in NIRKO mice, or in rats in which insulin 
receptor expression in the ARC and the PVN of the hypothalamus has been downregulated by 
antisense mRNA (58, 272). This provides direct evidence that hypothalamic neurons other 
than AgRP or POMC mediate insulin’s ability to suppress food intake. This is consistent with 
the recent suggestion that leptin’s effects in the VMH play an important role in controlling 
food intake (273), indicating that also leptin’s anorexigenic effects are not exclusively 
mediated by neurons located in the ARC. Furthermore, expression of the leptin receptor and 
its functional signaling in dopaminergic neurons of the VTA provided an interesting link 
between the hormonal control of food intake and the reward system. Hommel et al. could 
demonstrate that direct administration of leptin to the VTA caused a decreased food intake 
(205). Similarly, not only leptin receptors but also insulin receptors are expressed in the VMH 
as well as in dopaminergic neurons of the VTA. Indeed, the present study demonstrates that 
insulin signaling in the dopaminergic system regulates food intake. 
Another potentially contributing factor for the difference between NIRKO, IR∆AgRP 
and IR∆POMC mice may be that NIRKO mice also suffer from hypogonadism (58). IR∆AgRP and 
IR∆POMC mice exhibit normal fertility as assessed by litter-to-litter intervals, litter size and 
morphological assessment of reproductive organs. Thus, in addition to insulin receptor 
inactivation occurring in other neurons responsible for regulation of food intake, 
hypogonadism may be a confounding factor for the gender-specific obesity in NIRKO mice. 
Taken together, the results of the present study support the idea that neurons other than 
AgRP or POMC mediate insulin’s ability to suppress food intake. 
 
4.2.2 Role of insulin action on POMC and AgRP neurons in the regulation of glucose 
metabolism 
In 2002, Obici et al. demonstrated that hypothalamic insulin signaling is required for 
insulin’s ability to suppress hepatic glucose production in euglycemic-hyperinsulinemic 
clamps of rats (47, 48). In these studies injection of insulin receptor antisense mRNA 
specifically into the third ventricle of rats, or inactivating insulin receptor expression in the 
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mediobasal hypothalamus, inhibited insulin’s ability to suppress hepatic glucose production 
(47). Consistent with a role for central insulin action in regulation of hepatic glucose 
production, NIRKO mice show impaired suppression of hepatic glucose production in 
euglycemic-hyperinsulinemic clamps (48). Although in these studies inactivation of the 
insulin receptor co-localized with AgRP and POMC neurons, they left entirely open the 
question, whether insulin’s central effect to regulate hepatic glucose production is mediated 
by POMC, AgRP, other ARC or PVN neurons.  
The ARC has repeatedly been implicated as an important site for regulating peripheral 
glucose metabolism. Morton et al. demonstrated that rats lacking a functional leptin receptor 
presented with improved peripheral insulin sensitivity and glucose response following 
reconstituted expression of the leptin receptor or introduction of a constitutively active mutant 
of Akt in the ARC by adenoviral gene therapy (274). Importantly, this effect was not 
dependent on food intake and body weight. Gelling et al. overexpressed IRS 2 and Akt in the 
mediobasal hypothalamus of diabetic rats using adenoviral delivery (49). Here, the glycemic 
response to insulin was enhanced 2-fold, further indicating a role for PI3 kinase signaling in 
the mediobasal hypothalamus in regulation of peripheral glucose homeostasis. In conclusion, 
these results narrowed down the mediobasal hypothalamus as a critical region for regulation 
of peripheral glucose metabolism targeted by both insulin and leptin and controlled by the PI3 
kinase signaling pathway. A previous study has addressed the role of NPY in the regulation of 
hepatic glucose production (275). Although cerebral application of NPY blunts insulin’s 
ability to suppress hepatic glucose production, this type of pharmacological studies does not 
allow the delineation of whether the two pathways are physiologically interconnected or 
independently regulate hepatic glucose production. 
Therefore, cell type-specific ablation of signaling components in the hypothalamus 
clearly provides a definitive approach to unravel the functional significance of the recently 
recognized action of the hypothalamus to control glucose metabolism independent of body 
weight. The unique feasibility of this approach has also been revealed by the new insights 
gained from cell type-specific ablation or restoration of leptin and melanocortin signaling 
(164, 273). 
In the present study, insulin failed to normally suppress hepatic glucose production 
during euglycemic-hyperinsulinemic clamps in mice with an insulin receptor knockout 
specifically in AgRP neurons. The finding that AgRP neurons mediate insulin’s central effect 
on hepatic glucose production is consistent both anatomically and mechanistically with the 
above-described investigations by Obici and colleagues. Moreover, Obici et al. showed that 
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insulin’s ability to suppress hepatic glucose production depends on insulin-stimulated 
activation of the PI3 kinase pathway and can be inhibited by KATP channel blockers (47, 264). 
The finding of the present study that insulin stimulates POMC neuron hyperpolarization by 
direct interaction with insulin receptors on POMC neurons is consistent with these studies and 
previous reports that insulin inhibits electrical activity of POMC neurons by PIP3-dependent 
opening of KATP channels (202). 
The present study also directly shows that insulin treatment leads to membrane 
hyperpolarization and a decrease in action potential frequency in identified hypothalamic 
AgRP neurons and that this effect involves the activation of KATP channels. Consistent with 
the fact that insulin activates PI3 kinase in AgRP cells (276), and that these cells express KATP 
channels (263), these findings directly demonstrate that the mechanism by which insulin acts 
in POMC cells also holds true for AgRP neurons. In 2005, Pocai et al. demonstrated that 
insulin acts on KATP channels in hypothalamic neurons to control hepatic glucose production 
by decreasing glucose-6-phosphatase and phosphoenolpyruvate kinase expression in the liver 
(264). Transection of the vagal nerve to the liver blunted this effect, indicating a role for the 
autonomous nervous system in transmitting insulin’s central actions to the periphery. 
However, a recent study demonstrated that the effects of centrally applied NPY on hepatic 
glucose production are mediated via activation of sympathetic output to the liver (277). Thus, 
the exact downstream mechanism responsible for the effects of insulin action in the brain on 
hepatic glucose production remains to be established. 
Taken together, the results of the present study propose a new model that insulin 
activates PI3 kinase in AgRP cells, and that subsequent PIP3 formation results in KATP 
channel activation and electrical silencing of these cells. This may lead to a reduced release of 
the inverse melanocortin receptor agonist AgRP, NPY and/or other transmitters from AgRP 
neurons and thereby regulates innervation of the liver, which finally leads to suppression of 
hepatic glucose production (Figure 44).  
Recent findings implicate the cytokine IL-6 as insulin’s effector in the liver; it has 
been shown that insulin, acting through unidentified neurons in the CNS, regulates IL-6 
secretion from as-of-now uncharacterized cells in the liver (48). Furthermore, these studies 
demonstrated that hepatic IL-6 in turn activates STAT3 in liver parenchymal cells and inhibits 
glucose production, and insulin’s inhibiting effect on glucose production is blunted in animals 
lacking STAT3 in the liver (48). The findings that both insulin-induced IL-6 mRNA 
expression and suppression of glucose-6-phosphatase expression are blunted in mice lacking 
the insulin receptor specifically in AgRP neurons provide direct evidence in support of the 
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idea by Inoue et al. that insulin, acting through the CNS, regulates hepatic IL-6 expression to 
control gluconeogenesis via STAT3 activation in liver parenchymal cells and clearly indicates 
that insulin action on AgRP neurons is responsible for regulating this signaling cascade 
(Figure 44). 
 
Figure 44: Model of hepatic-regulation via insulin action on AgRP neurons. 
Cell autonomous action of insulin on AgRP neurons results in activation of the PI3 kinase (p85, regulatory 
subunit; p110, catalytic subunit) and generation of PIP3. PIP3 activates KATP channels, resulting in 
hyperpolarization and a decreased neuronal firing rate with subsequent reduced release of AgRP and/or other 
transmitters of AgRP neurons. This regulates innervation of the liver, leading to increased IL-6 expression. IL-6 
acting on liver parenchymal cells results in STAT3 phosphorylation via activation of JAK2, thereby leading to 
decreased expression of glucose-6-phosphatase (G6Pase). Abbreviations: G6P, glucose-6-phosphate; gp130, 
glycoprotein 130; IL-6R, interleukin-6 receptor alpha; JAK2, janus kinase 2; PIP2, phosphatidylinositol (4,5) 
bisphosphate; Pten, phosphatase and tensin homolog. 
 
Although IR∆AgRP mice do not display differences in glucose levels, both fasting 
glucose and glucose during tolerance testing represent an integration of production and 
utilization. Nevertheless, the present study clearly demonstrates that insulin action in AgRP 
neurons is essential for insulin-induced suppression of hepatic glucose production.  
Determination of tissue-specific glucose uptake rates showed similar rates of insulin-
stimulated glucose uptake in brain and skeletal muscle in IR∆AgRP mice compared to controls. 
However, insulin-stimulated glucose uptake in white adipose tissue of IR∆AgRP mice (but not 
IR∆POMC mice) was significantly increased compared to control mice. A similar increase in 
adipose glucose uptake has been observed in mice with selective inactivation of the insulin 
receptor in skeletal muscle (278). A recent study by Koch et al. indicated a role for central 
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insulin action in the neuronal control of lipogenesis in addition to the well-documented 
adipocyte-autonomous inhibition of lipolysis (279). Whether the increase in adipose glucose 
uptake in IR∆AgRP mice represents some form of compensatory response or tissue cross talk 
remains to be determined. 
However, the relative importance of hypothalamic insulin signaling for the overall 
control of hepatic glucose production has lately been matter of debate, since studies in dogs 
demonstrated that a 4-fold rise in cranial insulin levels does not change acute hepatic glucose 
output (280). Thus, differences between rodents and dogs as well as humans in acute and 
chronic regulation of glucose homeostasis need to be carefully addressed in future studies. 
 
4.3 Inactivation of the insulin receptor gene specifically in dopaminergic 
cells 
In the last years substantial evidence has emerged, that peripheral hormonal signals 
such as insulin and leptin are able to modulate the reward system of the brain. Both insulin 
and leptin receptors are co-expressed with tyrosine hydroxylase – a marker for dopamine 
neurons – in the ventral tegmental area (VTA) and substantia nigra (SN) (204). Furthermore, 
studies demonstrated that insulin and leptin administration into the VTA results in an 
increased formation of PIP3, the product of the PI3 kinase, which serves as an indicator for a 
functional signaling pathway (249). Hommel et al. investigated the functional relevance of 
leptin receptor expression in the VTA; they could demonstrate that VTA dopamine neurons 
respond to leptin with activation of the intracellular JAK/STAT pathway and a reduction in 
firing rate (205). Direct administration of leptin to the VTA resulted in a decreased food 
intake, while long-term RNAi-mediated knockdown of the leptin receptor in the VTA led to 
increased food intake, locomotor activity, and sensitivity to high-palatable food (205). Thus, 
these findings support a critical role for VTA leptin receptors in regulating feeding behavior 
and thereby provide functional evidence for direct action of a peripheral metabolic signal on 
VTA dopamine neurons.  
Intraventricular insulin administration prevents the expression of a place preference 
for high-fat food, decreases lick rates for sucrose solutions in a lickometer task, and decreases 
sucrose self-administration in rats that are not food deprived. Taken together, these findings 
support the hypothesis that insulin can blunt brain reward activity, including the rewarding 
attributes of food (247, 248, 281). However, the exact role of insulin signaling in 
dopaminergic cells has not been determined so far.  
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Therefore, to investigate the role of insulin signaling in dopaminergic cells in control 
of energy and glucose homeostasis, the insulin receptor gene was specifically inactivated in 
tyrosine hydroxylase (Th)-expressing cells by Cre-loxP-mediated recombination (IRΔTh mice). 
Th is the rate-limiting enzyme in dopamine synthesis and thus is a well-established marker of 
dopaminergic neurons. Consistent with previous studies (249), peripheral insulin 
administration resulted in robust PIP3 formation in identified Th-expressing cells in the VTA 
of control mice, supporting the notion that the insulin signaling pathway is functional and 
active in these cells. Importantly, insulin’s ability to activate the PI3 kinase pathway was 
blunted specifically in identified Th-expressing cells in the VTA of IRΔTh mice, indicating a 
successful inactivation of the insulin receptor in these cells. Taken together, mice with 
specific inactivation of the insulin receptor in Th-expressing cells provide an adequate tool to 
study the role of insulin signaling in dopaminergic cells in vivo. 
However, tyrosine hydroxylase is not only expressed in dopaminergic neurons of brain 
regions implicated in addiction and reward. Tyrosine hydroxylase is the first, rate-limiting 
enzyme in catecholamine synthesis and neurons of both the peripheral and central nervous 
system use catecholamines as neurotransmitters. In the periphery, the majority of sympathetic 
neurons are catecholaminergic; in the CNS the most abundant group of catcholaminergic cells 
are dopaminergic neurons of the mesencephalon (VTA and SN) (282). Additional groups of 
dopaminergic neurons reside in the medial zone incerta of the hypothalamus and the largest 
collection of norepinephrine-producing neurons is located in the locus coeruleus (282). Thus, 
Th-expression occurs not only in the VTA and the SN, but also in the sympathetic ganglia, 
adrenal medulla and the locus coeruleus. Therefore, additional studies are necessary to allow 
the delineation of insulin’s effects in the VTA and SN and possible effects of insulin in other 
Th-expressing cells. Nevertheless, the present study demonstrates direct effects of insulin on 
the dopaminergic system in the VTA, thus indeed indicating a role for insulin in this system. 
 
4.3.1 Role of insulin action on dopaminergic cells in the regulation of energy and 
glucose homeostasis 
IRΔTh mice display increased body weight under normal diet conditions, which is 
accompanied by increased adiposity and leptin levels. This indicates a critical role for insulin 
action on Th-expressing cells in regulation of energy homeostasis. The increase in body 
adiposity in these mice is not a consequence of decreased energy expenditure or a decrease in 
locomotor activity but occurs as a consequence of increased food intake, which could be 
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demonstrated both at 6 weeks and 13 weeks of age. A study by Figlewicz et al. could show 
that direct acute injection of insulin into the VTA blocks VTA-initiated feeding of sucrose 
pellets by administration of a µ-opioid agonist, supporting a role for insulin in control of 
feeding via its action in the dopaminergic system (249). However, VTA insulin injection 
alone did not change baseline sucrose pellet intake in this study, indicating that insulin’s 
effect on food reward may only be relevant when there is adequate stimulation or drive within 
the VTA (249). Nevertheless, the finding that IRΔTh mice display an increased food intake 
clearly demonstrates that insulin signaling in this system is important for the control of 
feeding behavior and thus reveals a novel role for insulin action in dopaminergic cells with 
respect to energy homeostasis. Further studies are necessary to investigate how these animals 
perform in behavioral paradigms with food as a reward. 
On the other hand, glucose metabolism is unaltered in mice with an insulin receptor 
knockout in Th-expressing cells under normal diet conditions. IRΔTh mice exhibit unaltered 
fasted blood glucose levels, glucose tolerance and insulin sensitivity at 10 and 11 weeks of 
age. While serum insulin levels are similar to controls at an age of 9 weeks, IRΔTh mice 
display increased serum insulin levels at an age of 20 weeks, which is consistent with 
increased adiposity in these animals. Therefore, additional studies in terms of glucose 
homeostasis are necessary in IRΔTh mice at approximately 20 weeks of age; this may reveal 
alterations in glucose tolerance and insulin sensitivity in these mice as a consequence of 
chronically elevated adiposity. 
 
4.3.2 Role of insulin action on dopaminergic cells in the regulation of gene expression 
and synaptic plasticity 
Figlewicz and colleagues suggested an additional potential target for insulin action on 
dopaminergic neurons: the dopamine transporter (DAT), which provides the primary 
mechanism through which extracellular dopamine is cleared from the synapses, thereby 
regulating the magnitude and duration of dopaminergic signaling (214). Insulin signaling 
through the PI3 kinase- and Akt-pathway promotes cell-surface expression of the DAT in 
vitro (283). Chronic intracerebroventricular insulin treatment resulted in an increased DAT 
mRNA expression in the VTA/SN and, consistent with this, food deprivation decreased 
expression and activity of DAT (284, 285).  
In the present study, expression analysis of different genes critically involved in 
dopamine signaling in brain regions related to the mesolimbic and nigrostriatal dopamine 
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system revealed that mRNA levels of Th and dopamine receptor 2 (D2R) are increased in the 
VTA of IRΔTh mice, while expression levels of DAT remained unchanged. Thus, the effect of 
chronic intracerebroventricular insulin treatment on DAT expression in the VTA either 
involves other neurons and/or synaptic transmission or the lack of insulin-stimulated DAT 
regulation can be physiologically compensated for when signaling by other hormonal or 
nutritional mediators is intact.  
A recent study demonstrated that food restriction increases mRNA levels of Th, DAT 
and dopa decarboxylase in the VTA of rats, and DAT protein expression was also upregulated 
in the NAc (286). The authors suggested that chronic food restriction, in which insulin and 
leptin levels are low, results in a sensitization of the mesolimbic dopamine pathway 
characterized by increased clearance of extracellular dopamine in the NAc. Furthermore they 
indicate that adipostatic hormones such as insulin and leptin are potential factors mediating 
these effects, directly or indirectly. D2Rs are localized both on neurons targeted by 
dopaminergic afferences but also on presynaptic dopaminergic neurons. Here, D2 presynaptic 
receptors are involved in regulation of dopamine synthesis and release (287-290). Thus, 
increased Th and D2R mRNA expression in the VTA of IRΔTh mice points to a sensitization of 
the mesolimbic dopamine pathways, however, this hypothesis awaits further experimental 
proof in future studies. 
In the present study, longterm euglycemic-hyperinsulinemic clamps in wild type mice 
demonstrated that prolonged insulin action in vivo results in a decrease of excitatory inputs on 
dopaminergic neurons in the VTA. The ratio of excitatory to inhibitory synaptic input on a 
neuron determines not only direct cell-autonomous regulation of cell electrical activity but 
also the set point of cell excitability (291). However, in the present study it is not clear 
whether the observed effects result from insulin action on postsynaptic (dopaminergic) 
neurons, on the presynaptic projecting neurons, or on both. Nevertheless, these results 
indicate that insulin exerts direct, inhibitory effects on the dopaminergic system of the brain. 
 
4.4 Perspectives 
Inactivation of the insulin receptor gene in AgRP-expressing neurons revealed a role 
for insulin action in these cells in regulation of hepatic glucose production. Further studies 
will be needed to identify and analyze further potential factors and neuronal circuits involved 
in neuronal transmission that finally results in hepatic innervation to regulate glucose 
production. Nevertheless, modulation of AgRP neuron-mediated regulation of hepatic glucose 
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production could provide an approach to support therapeutic control of insulin resistance in 
type 2 diabetes mellitus.  
Moreover, inactivation of the insulin receptor gene in Th-expressing cells defined a 
new role for insulin signaling in these cells in control of food intake and body weight. 
However, further studies are necessary to assess the functional role of insulin action in the 
dopaminergic system and to what extent multisynaptic transmission is involved. Expanding 
our knowledge of how insulin regulates energy homeostasis and how its action is integrated in 
multiple brain circuits is pivotal for a better understanding of the pathomechanisms 
responsible for the growing obesity epidemic. 
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5 Summary 
The finding that peripheral hormones, such as insulin and leptin directly can 
communicate to the hypothalamus to control energy homeostasis and glucose metabolism has 
set the ground for detailed understanding of the neuronal circuitry underlying the control of 
body weight homeostasis. Recent studies have implicated that insulin-stimulated activation of 
phosphatidylinositol 3 kinase signaling and the regulation of ATP-dependent potassium 
(KATP) channels in the hypothalamus is involved in the control of peripheral glucose 
metabolism. However, these experiments leave open the question of which specific neurons in 
these areas of the brain are responsible for mediating insulin’s effect.  
Here, mouse models with specific inactivation of the insulin receptor in either 
anorexigenic proopiomelanocortin (POMC)- or orexigenic agouti-related peptide (AgRP)-
expressing neurons of the arcuate nucleus of the hypothalamus are described. While neither 
POMC- nor AgRP-restricted insulin receptor knockout mice exhibited altered energy 
homeostasis, insulin failed to normally suppress hepatic glucose production during 
euglycemic-hyperinsulinemic clamps in mice with an insulin receptor knockout specifically in 
AgRP neurons. These mice exhibited reduced insulin-stimulated hepatic interleukin-6 
expression and increased hepatic expression of glucose-6-phosphatase. Additionally, insulin 
treatment resulted in membrane hyperpolarization and a decrease in action-potential 
frequency in identified hypothalamic AgRP neurons and this effect involved the activation of 
KATP channels, indicating that the same mechanism by which insulin acts in POMC cells also 
holds true for AgRP neurons. 
Taken together, these results directly demonstrate that insulin action in POMC and 
AgRP cells is not required for steady state regulation of food intake and body weight. 
However, insulin action specifically in AgRP-expressing neurons does play a critical role in 
controlling hepatic glucose production, raising the possibility that dysregulation of the 
insulin-AgRP pathway may contribute to the development of type 2 diabetes mellitus. 
Furthermore, there is much evidence that this basic homeostatic type of regulation of 
energy homeostasis by the hypothalamus relies on a complex intra-hypothalamic neuronal 
circuitry but also can be overruled by higher brain functions influenced by the addictive value 
of palatable food as well as its visual and gustatory aspects. Here, analysis of mice with 
specific inactivation of the insulin receptor in dopaminergic cells revealed an important new 
role for insulin signaling in these cells in regulation of food intake and energy homeostasis. 
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6  Zusammenfassung 
Die Erkenntnis, dass periphere Signalmoleküle, wie Insulin und Leptin, dem Gehirn 
den Energiestatus des Körpers übermitteln können und somit die Energiehomöostase und den 
Glukosestoffwechsel beeinflussen, legte den Grundstein für ein detaillierteres Verständnis der 
an dieser Übermittlung beteiligten Neuronenpopulationen. Untersuchungen der letzten Jahre 
konnten zeigen, dass die Insulin-vermittelte Aktivierung der Phosphatidyl-Inositol 3 Kinase 
und die Stimulation ATP-sensitiver Kaliumkanäle (KATP Kanäle) im Hypothalamus an der 
Regulation des peripheren Glukosestoffwechsels beteiligt sind. Jedoch konnten diese Studien 
nicht die genaue Identität der beteiligten Neuronenpopulationen klären. Hier werden zwei 
Mausmodelle mit einer spezifischen Inaktivierung des Insulinrezeptors in anorexigenen 
Proopiomelanocortin (POMC)- und in orexigenen Agouti-Related Peptide (AgRP)-
exprimierenden Neuronen beschrieben. Während weder Mäuse mit einer Inaktivierung des 
Insulinrezeptors in POMC- oder AgRP-Neuronen Veränderungen in der Energiehomöostase 
aufwiesen, war eine normale Supprimierung der hepatischen Glukoseproduktion während 
einer Euglykämischen-Hyperinsulinämischen Clamp-Untersuchung in Mäusen mit einer 
Insulinrezeptor-Inaktivierung in AgRP-Neuronen nicht mehr möglich. Weiterhin zeigte sich 
bei diesen Tieren eine reduzierte Insulin-stimulierte Expression von Interleukin-6 und eine 
erhöhte Expression des Enzyms Glukose-6-Phosphatase in der Leber. Zusätzlich wird hier 
gezeigt, dass Insulin zu einer Hyperpolarisierung und einer reduzierten Feuerrate in 
identifizierten AgRP-Neuronen führt; vermittelt durch die Aktivierung von KATP Kanälen. 
Somit konnten Ergebnisse aus elektrophysiologischen Studien mit POMC-Zellen auch für 
AgRP-Neurone bestätigt werden. Zusammenfassend zeigen diese Ergebnisse, dass die 
Insulinwirkung in POMC- und AgRP-Zellen nicht für eine normale Regulation von 
Nahrungsaufnahme und Körpergewicht von Bedeutung ist. Jedoch ist die Insulinwirkung in 
AgRP-Zellen von entscheidender Bedeutung in der Regulation der hepatischen 
Glukoseproduktion. Störungen des Insulinsignalwegs in AgRP-Neuronen könnten daher an 
der Entstehung des Diabetes Mellitus Typ 2 beteiligt sein. 
Weiterhin gibt es vermehrt Hinweise darauf, dass die Regulation der 
Energiehomöostase über Neurone im Hypothalamus durch höhere Hirnfunktionen und die 
suchterzeugende Wirkung von wohlschmeckender Nahrung beeinflusst werden kann. Hier 
zeigte die Analyse von Mäusen mit einer Inaktivierung des Insulinrezeptors in dopaminergen 
Zellen, dass dem Insulinsignalweg in diesen Zellen eine wesentliche Bedeutung in der 
Regulation der Nahrungsaufnahme und Energiehomöostase zukommt. 
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